( (TITLE (S (NP-SBJ (NP (DT A) (ADJP (NP (NN KATP) (NN Channel)) (HYPH -) (JJ Dependent)) (NN Pathway)) (PP-LOC (IN within) (NP (NN α) (NNS Cells)))) (VP (VBZ Regulates) (NP (NP (NN Glucagon) (NN Release)) (PP (IN from) (NP (NP (DT Both) (UCP (NN Rodent) (CC and) (JJ Human)) (NNS Islets)) (PP (IN of) (NP (NNS Langerhans))))))))) )
( (HEADING (NP (NN Abstract))) )
( (S (NP-SBJ (NP (NN Glucagon)) (, ,) (VP (VBN secreted) (NP (-NONE- *)) (PP (IN from) (NP (JJ pancreatic) (NN islet) (NN α) (NNS cells))))) (, ,) (VP (VBZ stimulates) (NP (NP (NN gluconeogenesis)) (CC and) (NP (NML (NN liver) (NN glycogen)) (NN breakdown)))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NN mechanism)) (VP (VBG regulating) (NP (NN glucagon) (NN release)))) (VP (VBZ is) (VP (VP (VBN debated) (NP-1 (-NONE- *))) (, ,) (CC and) (VP (ADVP (RB variously)) (VBN attributed) (NP-1 (-NONE- *)) (PP (PP (IN to) (NP (NP (JJ neuronal) (NN control)) (, ,) (NP (NP (JJ paracrine) (NN control)) (PP (IN by) (NP (VBG neighbouring) (NN β) (NNS cells)))))) (, ,) (CC or) (PP (IN to) (NP (NP (DT an) (JJ intrinsic) (NN glucose) (VBG sensing)) (PP (IN by) (NP (NP (DT the) (NN α) (NNS cells)) (NP (PRP themselves)))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD examined) (NP (NP (NN hormone) (NN secretion)) (CC and) (NP (NP (NN Ca2+) (NNS responses)) (PP (IN of) (NP (NML (NN α) (CC and) (NN β)) (NNS cells))))) (PP-LOC (IN within) (NP (NP (JJ intact) (NN rodent)) (CC and) (NP (JJ human) (NNS islets))))) (. .)) )
( (S (NP-SBJ (NP (ADJP (NN Glucose) (HYPH -) (JJ dependent)) (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN release)))) (VP (VBD persisted) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (NP (JJ paracrine) (NN GABA)) (CC or) (NP (NN Zn2+) (NN signalling))) (VP (VP (VP (VBD was) (VP (VBN blocked) (NP-1 (-NONE- *)))) (, ,) (CC but) (VP (VBD was) (VP (VBN reversed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (JJ low) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (SYM –) (CD 20)) (NNS μM)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (ADJP (NN ATP) (HYPH -) (JJ sensitive)) (NN K+) (PRN (-LRB- -LRB-) (NP (NN KATP)) (-RRB- -RRB-)) (NN channel) (NN opener)) (NP (NN diazoxide))))))))) (ADVP-TMP-2 (-NONE- *T*)) (, ,) (SBAR-ADV (WHNP-3 (WDT which)) (S (NP-SBJ-3 (-NONE- *T*)) (VP (VBD had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN insulin) (NN release)) (CC or) (NP (NML (NN β) (NN cell)) (NNS responses)))))))))))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN effect)) (VP (VBD was) (VP (VBN prevented) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT the) (NN KATP) (NN channel) (NN blocker)) (NP (NN tolbutamide)) (PRN (-LRB- -LRB-) (NP (CD 100) (NNS μM)) (-RRB- -RRB-)))))) (. .)) )
( (S (NP-SBJ (JJR Higher) (NN diazoxide) (NNS concentrations) (PRN (-LRB- -LRB-) (NP (QP (SYM ≥) (CD 30)) (NNS μM)) (-RRB- -RRB-))) (VP (VBN decreased) (NP (NP (NML (NN glucagon) (CC and) (NN insulin)) (NN secretion)) (, ,) (CC and) (NP (NML (NML (NN α) (HYPH -) (CC and) (NN β)) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses))) (, ,) (PP (IN in) (ADJP (JJ parallel)))) (. .)) )
( (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN glucose))))) (, ,) (NP-SBJ (NP (NN tolbutamide)) (PP (IN at) (NP (JJ low) (NNS concentrations) (PRN (-LRB- -LRB-) (NP (QP (SYM <) (CD 1)) (NN μM)) (-RRB- -RRB-))))) (VP (VBN stimulated) (NP (NN glucagon) (NN secretion)) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ (JJ high) (NNS concentrations) (PRN (-LRB- -LRB-) (NP (QP (SYM >) (CD 10)) (NNS μM)) (-RRB- -RRB-))) (VP (VBD were) (ADJP-PRD (JJ inhibitory)))))) (. .)) )
( (S (PP (IN In) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT a) (ADJP (RB maximally) (JJ inhibitory)) (NN concentration)) (PP (IN of) (NP (NN tolbutamide))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NNS mM)) (-RRB- -RRB-)))))) (, ,) (NP-SBJ (NN glucose)) (VP (VBD had) (NP (DT no) (JJ additional) (JJ suppressive) (NN effect))) (. .)) )
( (S (ADVP-LOC (RB Downstream) (PP (IN of) (NP (DT the) (NN KATP) (NN channel)))) (, ,) (NP-SBJ (NP (NN inhibition)) (PP (IN of) (NP (NP (NML (NML (NML (NN voltage) (HYPH -) (VBN gated)) (NN Na+) (PRN (-LRB- -LRB-) (NP (NN TTX)) (-RRB- -RRB-))) (CC and) (NML (NML (NN N) (HYPH -) (NN type)) (NN Ca2+))) (NNS channels) (PRN (-LRB- -LRB-) (NP (NN ω) (HYPH -) (NN conotoxin)) (-RRB- -RRB-))) (, ,) (CC but) (RB not) (NP (NML (NN L) (HYPH -) (NN type)) (NN Ca2+) (NNS channels) (PRN (-LRB- -LRB-) (NP (NN nifedipine)) (-RRB- -RRB-)))))) (, ,) (VP (VBD prevented) (NP (NN glucagon) (NN secretion))) (. .)) )
( (S (NP-SBJ-1 (CC Both) (NP (DT the) (NML (NN N) (HYPH -) (NN type)) (NN Ca2+) (NNS channels)) (CC and) (NP (NML (NN α) (HYPH -) (NN cell)) (NN exocytosis))) (VP (VBD were) (VP (VBN inactivated) (NP-1 (-NONE- *)) (PP (IN at) (NP (VBN depolarised) (NN membrane) (NNS potentials))))) (. .)) )
( (S (NP-SBJ-1 (UCP (NN Rodent) (CC and) (JJ human)) (NN glucagon) (NN secretion)) (VP (VBZ is) (VP (VBN regulated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (DT an) (NML (NN α) (HYPH -) (NN cell)) (ADJP (NP (NN KATP) (NN channel)) (HYPH -) (JJ dependent)) (NN mechanism))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (VBN elevated) (NN glucose)) (VP (VBZ reduces) (NP (NP (JJ electrical) (NN activity)) (CC and) (NP (NN exocytosis))) (PP-MNR (IN via) (NP (NP (ADJP (NN depolarisation) (HYPH -) (VBN induced)) (NN inactivation)) (PP (IN of) (NP (NP (NN ion) (NNS channels)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (NP (NN action) (NN potential) (NN firing)) (CC and) (NP (NN secretion))))))))))))) (. .)) )
( (HEADING (NP (NN Author) (NN Summary))) )
( (S (NP-SBJ (NN Glucagon)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ critical) (NN regulator)) (PP (IN of) (NP (NN glucose) (NN homeostasis))))) (. .)) )
( (S (NP-SBJ (PRP$ Its) (JJ major) (NN action)) (VP (VBZ is) (S-PRD (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB mobilize) (NP (NP (NN glucose)) (PP (IN from) (NP (DT the) (NN liver)))))))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Glucagon) (NN secretion)) (PP (IN from) (NP (NP (NN α) (NNS cells)) (PP (IN of) (NP (NP (DT the) (JJ pancreatic) (NNS islets)) (PP (IN of) (NP (NNP Langerhans)))))))) (VP (VBZ is) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (VBN elevated) (NN blood) (NN sugar)) (, ,) (NP (NP (DT a) (NN response)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBZ is) (ADVP (RB often)) (VP (VBN perturbed) (NP-2 (-NONE- *)) (PP (IN in) (NP (NN diabetes)))))))))))) (. .)) )
( (S (NP-SBJ (JJ Much) (NN work)) (VP (VBZ has) (VP (VBN focused) (PP (IN on) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NML (NN α) (HYPH -) (NN cell)) (NN glucagon) (NN secretion))) (PP (PP (IN by) (NP (JJ neuronal) (NNS factors))) (CC and) (PP (IN by) (NP (NP (JJ paracrine) (NNS factors)) (PP (IN from) (NP (VBG neighbouring) (NNS cells))) (, ,) (PP (VBG including) (NP (NP (DT the) (JJ important) (NN islet) (NN hormone)) (NP (NN insulin))))))))))) (. .)) )
( (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (PRP we)) (VP (VBP provide) (NP (NP (NN evidence)) (PP (IN in) (NP (NP (NN support)) (PP (IN of) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN of) (NP (NN glucose))) (PP (IN on) (NP (NN α) (NNS cells))) (PP-LOC (IN within) (NP (JJ intact) (UCP (NN rodent) (CC and) (JJ human)) (NNS islets))))))))) (. .)) )
( (S (ADVP (RB Notably)) (, ,) (NP-SBJ (PRP$ our) (NN work)) (VP (VBZ implicates) (NP (NP (NP (DT an) (NML (NN α) (HYPH -) (NN cell)) (NML (NN glucose) (HYPH -) (VBG sensing)) (NN pathway)) (ADJP (JJ similar) (PP (IN to) (NP (NP (DT that)) (VP (VBN found) (NP (-NONE- *)) (PP-LOC (IN in) (NP (ADJP (NN insulin) (HYPH -) (VBG secreting)) (NN β) (NNS cells)))))))) (, ,) (VP (VBG involving) (NP (NP (NN closure)) (PP (IN of) (NP (ADJP (NN ATP) (HYPH -) (JJ dependent)) (NN K+) (NNS channels))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN glucose))))))))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBP find) (SBAR (IN that) (S (NP-SBJ (NN membrane) (NN depolarisation)) (VP (VBZ results) (PP (IN in) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NML (NML (NN Na+) (CC and) (NN Ca2+)) (NN channel)) (NN activity)) (CC and) (NP (NML (NN α) (HYPH -) (NN cell)) (NN exocytosis)))))))))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (VBN elevated) (NN blood) (NN glucose)) (VP (VBZ reduces) (NP (NP (NML (NN α) (HYPH -) (NN cell)) (JJ electrical) (NN activity)) (CC and) (NP (NN glucagon) (NN secretion))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG inactivating) (NP (NP (DT the) (NN ion) (NNS channels)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (NP (NN action) (NN potential) (NN firing)) (CC and) (NP (NN secretion))))))))))))) (. .)) )
( (HEADING (NP (NN Introduction))) )
( (S (NP-SBJ (NN Blood) (NN glucose) (NNS levels)) (VP (VBP are) (PP-PRD (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (CD two) (NNS hormones)) (VP (VBN released) (NP (-NONE- *)) (PP (IN from) (NP (NP (DT the) (JJ pancreatic) (NNS islets)) (PP (IN of) (NP (NNP Langerhans))))))))))) (. .)) )
( (S (NP-SBJ (NN Islet) (NN β) (NNS cells)) (VP (VBP secrete) (NP (NN insulin)) (SBAR-TMP (WHADVP-1 (WRB when)) (S (NP-SBJ (NN glucose)) (VP (VBZ is) (ADJP-PRD (JJ high)) (ADVP-TMP-1 (-NONE- *T*))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG decreasing) (NP (NP (NN glucose) (NN production)) (PP (IN by) (NP (DT the) (NN liver))))) (CC and) (VP (VBG increasing) (NP (NP (NN glucose) (NN storage)) (PP-LOC (IN in) (NP (JJ multiple) (NNS tissues)))))))) (. .)) )
( (S (NP-SBJ-1 (VBN Regulated) (NN insulin) (NN secretion)) (VP (VBZ is) (ADVP (RB relatively) (RB well)) (VP (VBN understood) (NP-1 (-NONE- *)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG involving) (NP (NP (DT the) (JJ metabolic) (NN stimulation)) (PP (IN of) (NP (NP (JJ electrical) (NN activity)) (, ,) (NP (NN Ca2+) (NN entry)) (, ,) (CC and) (NP (NN exocytosis))))))) (PRN (-LRB- [) (NP (CD 1)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (NN Islet) (NN α) (NNS cells)) (VP (VBP secrete) (NP (NN glucagon)) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (VBN decreased) (NN blood) (NN glucose))))) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ (VBN elevated) (NN glucose) (NNS levels)) (VP (VBP suppress) (NP (NN glucagon) (NN release)))))) (. .)) )
( (S (NP-SBJ (NN Glucagon)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ principal) (NN factor)) (VP (VBG stimulating) (NP (NP (NN glucose) (NN production)) (PP (IN by) (NP (DT the) (NN liver))))))) (. .)) )
( (S (PP (IN In) (NP (NN diabetes))) (, ,) (S (S (NP-SBJ-2 (NN baseline) (NN glucagon) (NN release)) (VP (VBZ is) (ADJP-PRD (JJ elevated)))) (, ,) (CC and) (S (NP-SBJ-1 (NP (NN glucagon) (NN secretion)) (PP (IN in) (NP (DT the) (NML (JJ low) (HYPH -) (NN glucose)) (NN condition)))) (VP (VBZ is) (VP (VBN blunted) (NP-1 (-NONE- *))))) (PRN (-LRB- [) (NP (NP (CD 2)) (PP (SYM –) (NP (CD 4)))) (-RRB- ]))) (. .)) )
( (S (NP-SBJ (DT These) (NNS effects)) (VP (VBP contribute) (PP (PP (IN to) (NP (JJ chronic) (NN hyperglycaemia))) (CC and) (PP (IN to) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN for) (NP (JJ acute) (JJ hypoglycaemic) (NNS events))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NN mechanism)) (VP (VBG regulating) (NP (NN glucagon) (NN secretion)))) (VP (VP (VBZ is) (ADVP (RB poorly)) (VP (VBN understood) (NP-1 (-NONE- *)))) (CC and) (VP (VBZ remains) (ADJP-PRD (RB hotly) (VBN debated))) (PRN (-LRB- [) (NP (CD 5)) (-RRB- ]))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Glucagon) (NN release)) (PP-LOC (IN in) (NP (NNS rodents)))) (VP (MD may) (VP (VB be) (VP (VBN regulated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (JJ paracrine) (NNS signals)) (, ,) (PP (VBG including) (NP (NP (NP (NN γ) (HYPH -) (JJ aminobutyric) (NN acid)) (-LRB- -LRB-) (NP (NN GABA)) (-RRB- -RRB-) (PRN (-LRB- [) (NP (CD 6) (, ,) (CD 7)) (-RRB- ]))) (, ,) (NP (NN Zn2+) (PRN (-LRB- [) (NP (CD 8)) (-RRB- ]))) (, ,) (CC and) (NP (NN insulin) (PRN (-LRB- [) (NP (CD 9) (, ,) (CD 10)) (-RRB- ])))))))))) (. .)) )
( (S (ADVP (RB Conversely)) (, ,) (NP-SBJ (NN glucose)) (VP (MD may) (VP (VB suppress) (NP (NN glucagon) (NN secretion)) (PP-MNR (IN through) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN on) (NP (NML (NN α) (HYPH -) (NN cell)) (NN activity))))) (PRN (-LRB- [) (NP (NP (CD 11)) (PP (SYM –) (NP (CD 14)))) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (EX There)) (VP (VBP are) (ADVP (RB also)) (NP-PRD (NP (NNS studies)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN glucagon) (NN secretion)) (VP (VBZ is) (PP-PRD (IN under) (NP (JJ hypothalamic) (NN control)))))))) (PRN (-LRB- [) (NP (CD 15) (, ,) (CD 16)) (-RRB- ]))) (. .)) )
( (S (S (NP-SBJ (JJ Human) (ADJP (FW in) (FW vivo)) (NNS studies)) (VP (VBP provide) (NP (NP (VBG conflicting) (NN evidence)) (PP (VBG regarding) (NP (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NN glucagon) (NN secretion))) (PP (IN by) (NP (JJ paracrine)))) (CC or) (NP (NP (JJ intrinsic) (NN regulation)) (PP (IN of) (NP (NN α) (NNS cells))))))) (PRN (-LRB- [) (NP (NP (CD 17)) (PP (SYM –) (NP (CD 30)))) (-RRB- ])))) (, ,) (CC and) (S (NP-SBJ-1 (ADJP (RB very) (JJ little)) (NN work)) (VP (VBZ has) (VP (VBN been) (VP (VBN done) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB examine) (NP (DT this) (NN question)) (PP-LOC (IN in) (NP (VBN isolated) (JJ human) (NNS islets)))))))))) (. .)) )
( (S (NP-SBJ (NN Islet) (NN α) (NNS cells)) (VP (VBP express) (NP (NP (NML (NML (ADJP (NN ATP) (HYPH -) (JJ dependent)) (NN K+)) (-LRB- -LRB-) (NML (NN KATP))) (-RRB- -RRB-) (NNS channels) (PRN (-LRB- [) (NP (CD 9) (, ,) (CD 13) (, ,) (CD 14) (, ,) (CD 31) (, ,) (CD 32)) (-RRB- ]))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD can) (VP (VB be) (VP (VBN closed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN ATP))))))))) (PRN (-LRB- [) (NP (CD 9) (, ,) (CD 31)) (-RRB- ]))) (. .)) )
( (S (NP-SBJ (NN Glucose)) (VP (VBZ increases) (NP (JJ intracellular) (JJ free) (NN ATP)) (PP-LOC (IN in) (NP (NN α) (NNS cells))) (PRN (-LRB- [) (NP (CD 8) (, ,) (CD 10)) (-RRB- ])) (, ,) (SBAR-ADV (IN although) (S (NP-SBJ (NNS reports)) (VP (VBP vary) (PP (IN as) (PP (IN to) (NP (NP (DT the) (NN ability) (S-1 (-NONE- *ICH*))) (PP (IN of) (NP (NN glucose))) (S-1 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB inhibit) (NP (NML (NN α) (HYPH -) (NN cell)) (NN KATP) (NNS channels)))))))) (PRN (-LRB- [) (NP (CD 13) (, ,) (CD 31) (, ,) (CD 33)) (-RRB- ])))))) (. .)) )
( (S (NP-SBJ (NP (NN Evidence)) (PP (IN from) (NP (NML (NN SUR1) (SYM −) (HYPH /) (SYM −)) (NNS mice)))) (VP (VBP implicate) (NP (NN KATP) (NNS channels)) (PP (IN as) (NP (NP (NNS regulators)) (PP (IN of) (NP (NN glucagon) (NN release))))) (PRN (-LRB- [) (NP (CD 13) (, ,) (CD 34) (, ,) (CD 35)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB However)) (, ,) (SBAR-PRP (IN because) (S (NP-SBJ (NML (CC both) (NN α) (CC and) (NN β)) (NNS cells)) (VP (VBP possess) (NP (ADJP (RB molecularly) (JJ identical)) (NN KATP) (NNS channels)) (PRN (-LRB- [) (NP (CD 36) (, ,) (CD 37)) (-RRB- ]))))) (, ,) (NP-SBJ (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (RB not) (ADJP-PRD (JJ clear)) (SBAR-1 (WHADVP-2 (WRB how)) (S (NP-SBJ (ADJP (NN KATP) (HYPH -) (VBN mediated)) (NN depolarisation)) (VP (MD would) (VP (VP (VB stimulate) (NP (NN insulin) (NN secretion))) (CC but) (VP (VBP suppress) (NP (NN glucagon) (NN secretion))) (ADVP-MNR-2 (-NONE- *T*))))))) (. .)) )
( (S (NP-SBJ (DT The) (NN answer)) (VP (MD may) (VP (VB lie) (PP (IN in) (NP (NP (DT the) (JJ downstream) (NN machinery)) (VP (VBG regulating) (NP (NP (JJ electrical) (NN activity)) (CC and) (NP (NN Ca2+) (NN entry)))))))) (. .)) )
( (S (PP (IN Unlike) (NP (NN β) (NNS cells))) (, ,) (NP-SBJ (NN α) (NNS cells)) (VP (VBP possess) (NP (NP (DT a) (JJ large) (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN Na+) (NN current)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NN glucagon) (NN release)))))))) (PRN (-LRB- [) (NP (CD 14) (, ,) (CD 33)) (-RRB- ]))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN proposed) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (ADJP (NN depolarisation) (HYPH -) (VBN induced)) (NN inactivation)) (PP (IN of) (NP (DT this) (NN channel)))) (VP (VBZ contributes) (PP (IN to) (NP (NP (DT the) (NN cessation)) (PP (IN of) (NP (NN action) (NN potential) (NN firing)))))))) (PRN (-LRB- [) (NP (CD 14)) (-RRB- ])))) (. .)) )
( (S (ADVP (RB Additionally)) (, ,) (NP-SBJ (NP (NN activation)) (PP (IN of) (NP (NP (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN Ca2+) (NNS channels)) (-LRB- -LRB-) (NP (NNS VDCCs))))) (-RRB- -RRB-) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP-PRP (IN for) (NP (NP (NN Ca2+) (NN entry)) (CC and) (NP (NML (NN α) (HYPH -) (NN cell)) (NN function))))) (PRN (-LRB- [) (NP (CD 38) (, ,) (CD 39)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB Accordingly)) (, ,) (NP-SBJ-1 (NP (DT the) (NML (NN α) (HYPH -) (NN cell)) (JJ intracellular) (NN Ca2+) (PRN (-LRB- -LRB-) (NP (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (-RRB- -RRB-)) (NNS oscillations)) (VP (-LRB- -LRB-) (VBG reflecting) (NP (NML (NN α) (HYPH -) (NN cell)) (JJ electrical) (NN activity)))) (-RRB- -RRB-) (VP (VBP are) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP (IN in) (NP (NP (NN parallel)) (PP (IN with) (NP (NP (NN glucagon) (NN release)) (PP (IN by) (NP (NN glucose))))))) (PRN (-LRB- [) (NP (CD 40)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (JJ Multiple) (NNS VDCCs)) (VP (VBP regulate) (NP (NN glucagon) (NN release)) (PRN (-LRB- [) (NP (CD 14)) (, ,) (NP (NP (CD 41)) (PP (SYM –) (NP (CD 43)))) (-RRB- ])) (, ,) (SBAR-ADV (IN although) (S (NP-SBJ-1 (DT the) (NML (NN N) (HYPH -) (NN type)) (NNS channels)) (VP (VBP appear) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB be) (ADJP-PRD (RB particularly) (JJ important) (PP (IN for) (NP (NP (NN glucagon) (NN release)) (VP (VBN evoked) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NP (NN hypoglycaemia)) (ADVP (RB alone)))))))) (PRN (-LRB- [) (NP (CD 33) (, ,) (CD 44) (, ,) (CD 45)) (-RRB- ])) (, ,) (PP-LOC (ADVP (RB at) (RBS least)) (IN in) (NP (NN mouse) (NNS islets)))))))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VBZ is) (PP-PRD (IN in) (NP (NP (NN contrast)) (PP (IN to) (NP (NP (DT the) (NN β) (NN cell)) (SBAR (WHPP-1 (IN in) (WHNP (WDT which))) (S (NP-SBJ (DT the) (NML (NN L) (HYPH -) (NN type)) (NN VDCC)) (ADVP (RB functionally)) (VP (VBZ predominates) (PP-LOC-1 (-NONE- *T*))))))))) (PRN (-LRB- [) (NP (CD 46)) (-RRB- ]))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB now)) (VP (VBN compared) (NP (NP (NML (NN insulin) (CC and) (NN glucagon)) (NN release)) (CC and) (NP (NML (NML (NN α) (HYPH -) (CC and) (NN β)) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses))) (PP-LOC (IN in) (NP (JJ intact) (UCP (NN mouse) (, ,) (NN rat) (, ,) (CC and) (JJ human)) (JJ pancreatic) (NNS islets))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN glucose)) (VP (VBD retained) (NP (DT the) (NN ability) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB suppress) (NP (NN glucagon) (NN release)) (PP (PP (IN from) (NP (NP (VBN isolated) (NNS islets)) (PP-TMP (IN during) (NP (NP (NN blockade)) (PP (IN of) (NP (DT the) (NML (NN Zn2+) (CC and) (NN GABA)) (JJ paracrine) (NNS pathways))))))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (VBN stimulated) (NN insulin) (NN secretion)) (CC or) (NP (NML (NN β) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses))))))))))))))) (. .)) )
( (S (ADVP (RB Thus)) (NP-SBJ (PRP we)) (ADVP (RB now)) (VP (VBP provide) (NP (NP (NP (NN evidence)) (PP-LOC (IN in) (NP (CC both) (UCP (NN rodent) (CC and) (JJ human)) (NNS islets)))) (VP (VBG supporting) (NP (NP (DT the) (JJ direct) (PRN (-LRB- -LRB-) (ADJP (JJ intrinsic)) (-RRB- -RRB-)) (NN glucose) (NN regulation)) (PP (IN of) (NP (NP (NN glucagon) (NN release)) (PP (IN from) (NP (JJ pancreatic) (NN α) (NNS cells))))))))) (. .)) )
( (HEADING (NP (NNS Results))) )
( (HEADING (S (NP-SBJ (NN Glucose)) (VP (MD Can) (VP (VB Regulate) (NP (NN Glucagon) (NN Secretion)) (ADVP (RB Directly)))))) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (VP (VB examine) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN GABA) (CC and) (NN Zn2+))) (PP (IN as) (NP (NP (JJ paracrine) (NNS mediators)) (PP (IN of) (NP (NN glucagon) (NN secretion))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN ability) (S-1 (-NONE- *ICH*))) (PP (IN of) (NP (NP (NP (DT the) (NN GABAA) (NN receptor) (NN antagonist)) (NP (NN SR) (HYPH -) (CD 95531))) (CC and) (NP (NP (NN Zn2+) (NN chelation)) (PP (IN with) (NP (NN Ca2+) (HYPH -) (NN EDTA)))))) (S-1 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (ADJP (NN glucose) (HYPH -) (JJ dependent)) (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN release))))))))) (. .)) )
( (S (NP-SBJ (NP (NN Glucose)) (, ,) (PP (IN at) (NP (NP (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (QP (CD 7) (CC and) (CD 8.3)) (NN mM)) (-RRB- -RRB-)) (PP (ADVP (RB just)) (IN above) (NP (NP (DT the) (NN threshold)) (PP (IN for) (NP (NN insulin) (NN release))))))) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (ADVP (RB below)))) (-RRB- -RRB-))) (, ,) (VP (VBN suppressed) (NP (NN glucagon) (NN secretion)) (PP (IN from) (NP (VBN isolated) (NML (NN mouse) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1A)) (-RRB- -RRB-)) (CC and) (NN rat)) (NNS islets) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1B)) (-RRB- -RRB-)))) (PP (IN by) (NP (NP (CD 60) (NN %) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 15)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-))) (CC and) (NP (CD 57) (NN %) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 10)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-))))) (, ,) (ADVP (RB respectively))) (. .)) )
( (S (PP-LOC (IN In) (NP (CC both) (NML (NN mouse) (CC and) (NN rat)) (NNS islets))) (, ,) (NP-SBJ (NP (DT the) (NN ability) (S-1 (-NONE- *ICH*))) (PP (IN of) (NP (NN glucose))) (S-1 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB inhibit) (NP (NN glucagon) (NN secretion)))))) (VP (VBD persisted) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN Ca2+) (HYPH -) (NN EDTA) (PRN (-LRB- -LRB-) (NP (NP (CD 43) (NN %)) (CC and) (NP (CD 48) (NN %))) (, ,) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 10)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))) (CC and) (NP (NN SR) (HYPH -) (CD 95531) (PRN (-LRB- -LRB-) (NP (NP (CD 31) (NN %)) (CC and) (NP (CD 46) (NN %))) (, ,) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 8) (CC and) (CD 10)))) (, ,) (S (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (CC and) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ worth) (SBAR (WHNP-3 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (VBG noting) (NP-3 (-NONE- *T*)))))) (SBAR-1 (IN that) (S (S (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (NN GABAA) (NN antagonist))))) (, ,) (NP-SBJ-2 (NN glucagon) (NN secretion)) (VP (VBD was) (VP (VBN increased) (NP-2 (-NONE- *)) (PP (IN under) (NP (ADJP (CC both) (JJ low) (HYPH -) (CC and) (JJ high)) (HYPH -) (NN glucose) (NNS conditions)))))) (, ,) (CC and) (S (ADVP (RB furthermore)) (, ,) (NP-SBJ (NN glucose)) (VP (VBD was) (ADJP-PRD (NP (QP (RB approximately) (CD 50)) (NN %)) (RBR less) (JJ effective) (PP (IN in) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG suppressing) (NP (NP (NN glucagon) (NN release)) (PP (IN from) (NP (NN mouse) (NNS islets)))))))) (PRN (-LRB- -LRB-) (NP (NP (CD 31) (NN %)) (CC versus) (NP (CD 60) (NN %))) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-)))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1A)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Additionally)) (, ,) (NP-SBJ-1 (NP (NN somatostatin)) (VP (VBN released) (NP (-NONE- *)) (PP (IN from) (NP (JJ pancreatic) (NN δ) (NNS cells))))) (VP (VBZ is) (VP (VBN suggested) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB be) (NP-PRD (NP (DT a) (JJ potential) (JJ paracrine) (NN regulator)) (PP (IN of) (NP (NN glucagon) (NN secretion))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT the) (NML (NML (NN somatostatin) (NN receptor) (CD 2)) (-LRB- -LRB-) (NML (NN SSTR) (HYPH -) (CD 2))) (-RRB- -RRB-) (NN antagonist)) (NP (NN PRL) (HYPH -) (CD 2903))) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN ability) (S-1 (-NONE- *ICH*))) (PP (IN of) (NP (NP (NN glucose)) (-LRB- -LRB-) (PP (IN at) (NP (QP (CD 3) (CC and) (CD 7)) (NNS mM))))) (-RRB- -RRB-) (S-1 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB inhibit) (NP (NN glucagon) (NN secretion)) (PP (IN from) (NP (NN mouse) (NNS islets)))))))) (PRN (-LRB- [) (NP (CD 47)) (-RRB- ])))) (. .)) )
( (S (PP (IN Like) (NP (DT the) (NN GABAA) (NN receptor) (NN antagonist))) (, ,) (ADVP (RB however)) (, ,) (NP-SBJ (NN PRL) (HYPH -) (CD 2903)) (VP (VBD increased) (NP (NN glucagon) (NN secretion)) (PP (IN in) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NNS conditions))) (PRN (-LRB- [) (NP (CD 47)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (SBAR-ADV (IN although) (S (NP-SBJ (DT the) (JJ present) (NNS data)) (VP (VBP do) (RB not) (ADVP (RB entirely)) (VP (VB rule) (PRT (RP out)) (NP (DT these) (NNS pathways)) (PP (IN as) (NP (NP (NNS modulators)) (PP (IN of) (NP (NN glucagon) (NN secretion))))))))) (, ,) (NP-SBJ-1 (NN glucose)) (VP (VBZ is) (ADVP (RB clearly)) (ADJP-PRD (JJ able) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB suppress) (NP (NN glucagon) (NN secretion)) (ADVP (RB independently) (PP (IN of) (NP (DT these))))))))) (. .)) )
( (HEADING (S (NP-SBJ (NML (NN α) (HYPH -) (NN Cell)) (NN KATP) (NNS Channels)) (VP (VBP Regulate) (NP (NN Glucagon) (NN Secretion))))) )
( (S (NP-SBJ (PRP We)) (ADVP (RB next)) (VP (VBD examined) (NP (NML (NN glucagon) (CC and) (NN insulin)) (NN secretion)) (PP-TMP (IN during) (NP (NP (JJ pharmacological) (NN manipulation)) (PP (IN of) (NP (NN KATP) (NN channel) (NN activity)))))) (. .)) )
( (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN KATP) (NNS channels))) (PP-LOC (IN in) (NP (JJ intact) (NNS islets)))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG applying) (NP (DT an) (ADJP (ADJP (JJ indirect)) (, ,) (CC but) (ADJP (RB minimally) (JJ invasive))) (, ,) (NN technique))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (S-1 (-NONE- *EXP*))) (VP (MD would) (VP (VB have) (VP (VBN been) (ADJP-PRD (JJ difficult)) (PRN (-LRB- -LRB-) (SBAR (IN if) (FRAG (RB not) (ADJP-PRD (JJ impossible)))) (-RRB- -RRB-)) (S-1 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB study) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN glucose))) (PP (IN on) (NP (NML (NN α) (HYPH -) (NN cell)) (NML (NN KATP) (NN channel)) (NN activity)))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT the) (NML (NN patch) (HYPH -) (NN clamp)) (NN technique))))))) (PP-PRP (IN because) (IN of) (NP (NP (NP (DT the) (NN smallness)) (PP (IN of) (NP (DT the) (NML (NN α) (HYPH -) (NN cell)) (NN resting) (NN conductance)))) (-LRB- -LRB-) (NP (NP (NP (CD 0.15) (NNS nS)) (PP (SYM /) (NP (NN pF))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN glucose)))))) (, ,) (SBAR (WHPP-2 (IN of) (WHNP (WDT which))) (S (NP-SBJ (NP (CD two) (NNS thirds)) (PP (-NONE- *T*))) (VP (VBZ is) (ADJP-PRD (JJ attributable) (PP (IN to) (NP (NN KATP) (NNS channels)))))))) (-RRB- -RRB-))) (PRN (-LRB- [) (NP (CD 13)) (-RRB- ]))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP (RB instead)) (VP (VBN used) (NP (NP (VBG increasing) (NNS concentrations)) (PP (IN of) (NP (NN diazoxide) (CC and) (NN tolbutamide)))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (`` “) (VP (VB titrate) ('' ”) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NML (NN KATP) (NN channel)) (NN activity))) (PP (IN on) (NP (NP (NML (NN α) (HYPH -) (NN cell)) (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (CC and) (NP (NN glucagon) (NN secretion)))))))))) (. .)) )
( (S (NP-SBJ (NP (VBG Increasing) (NNS concentrations)) (PP (IN of) (NP (DT the) (NML (NN KATP) (NN channel)) (NN activator) (NN diazoxide)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NP (JJ moderate) (NN activation)) (PP (IN of) (NP (NN KATP) (NNS channels))) (PRN (-LRB- -LRB-) (NP (NML (QP (CD 0.3) (SYM –) (CD 10)) (NNS μM)) (NN diazoxide)) (-RRB- -RRB-))) (VP (VBD relieved) (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP (NP (NN glucagon) (NN secretion)) (PP (IN from) (NP (NML (CC both) (NML (NN mouse) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2A)) (-RRB- -RRB-))) (CC and) (NML (NN rat) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2B)) (-RRB- -RRB-)))) (NNS islets)))))))))) (. .)) )
( (S (NP-SBJ (NP (NN Stimulation)) (PP (IN of) (NP (NN glucagon) (NN release)))) (VP (VBD was) (ADJP-PRD (RB half) (HYPH -) (JJ maximal) (PP (IN at) (NP (NML (QP (RB approximately) (CD 1)) (NN μM)) (NN diazoxide)))) (, ,) (SBAR-ADV (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ is) (PP-LOC-PRD (ADVP (RB well)) (IN below) (NP (NP (DT that)) (VP (VBN required) (NP (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB inhibit) (NP (NN insulin) (NN release))))))))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (`` “) (NN re-activation)) ('' ”) (PP (IN of) (NP (NN glucagon) (NN release)))) (VP (VBD was) (RB not) (ADJP-PRD (JJ secondary) (PP (IN to) (NP (VBN reduced) (NML (NN β) (HYPH -) (NN cell)) (NN secretion)))))))))) (. .)) )
( (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG Increasing) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NN diazoxide)))) (PP (IN beyond) (NP (CD 10) (NNS μM))))) (VP (VBD inhibited) (NP (NN glucagon) (NN secretion)) (PP (IN in) (NP (NP (NN parallel)) (PP (IN with) (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (NN insulin) (NN release))) (PP (IN from) (NP (CC both) (NML (NN mouse) (CC and) (NN rat)) (NNS islets))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 2A) (CC and) (NN 2B))) (-RRB- -RRB-))) (. .)) )
( (S (SBAR-TMP (WHADVP-2 (WRB When)) (S (NP-SBJ-1 (-NONE- *PRO*)) (ADVP (RB instead)) (VP (VBN applied) (NP-1 (-NONE- *)) (ADVP-TMP-2 (-NONE- *T*)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NML (CD 1) (NN mM)) (NN glucose)) (-LRB- -LRB-) (SBAR (WHPP-4 (IN at) (WHNP (WDT which) (NN concentration))) (S (NP-SBJ-3 (NN glucagon) (NN secretion)) (VP (VBZ is) (VP (VBN stimulated) (NP-3 (-NONE- *)) (PP-4 (-NONE- *T*))))))))))))) (-RRB- -RRB-) (, ,) (NP-SBJ (VBG increasing) (NN diazoxide)) (VP (VBD produced) (NP (NP (DT a) (JJ monotonic) (NN inhibition)) (PP (IN of) (NP (NN glucagon) (NN secretion))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2C)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (DT a) (ADJP (RB half) (HYPH -) (JJ maximal)) (JJ inhibitory) (NN concentration) (PRN (-LRB- -LRB-) (NP (NN IC50)) (-RRB- -RRB-))) (SBAR (WHNP-5 (WDT that)) (S (NP-SBJ-5 (-NONE- *T*)) (VP (VBZ is) (ADJP-PRD (ADJP (RB much) (JJR lower)) (PP (IN than) (SBAR-NOM (WHNP-6 (WP what)) (S (NP-SBJ-6 (-NONE- *T*)) (VP (VBZ is) (VP (VBN seen) (NP-6 (-NONE- *)) (PP (IN under) (NP (NML (JJ high) (HYPH -) (NN glucose)) (NNS conditions))) (PRN (-LRB- -LRB-) (NP (NP (QP (SYM ∼) (CD 2)) (NNS μM)) (CC versus) (NP (QP (SYM ∼) (CD 50)) (NNS μM))) (-RRB- -RRB-))))))))))))))) (. .)) )
( (S (PP (IN In) (NP (NP (DT the) (JJ complete) (NN absence)) (PP (IN of) (NP (NN glucose))))) (, ,) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (NN KATP) (NNS channels)) (VP (VBP are) (VP (VBN expected) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB be) (ADJP-PRD (JJ open))))) (ADVP-TMP-2 (-NONE- *T*)))))) (, ,) (NP-SBJ (NP (DT the) (NML (NN KATP) (NN channel)) (NN antagonist)) (NP (NN tolbutamide))) (ADVP (RB also)) (VP (VBD produced) (NP (NP (DT a) (JJ biphasic) (NN effect)) (PP (IN on) (NP (NN glucagon) (NN release))))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Augmentation)) (PP (IN of) (NP (NN glucagon) (NN secretion)))) (VP (VBD was) (VP (VBN seen) (NP-1 (-NONE- *)) (PP (IN at) (NP (NP (NN tolbutamide) (NNS concentrations)) (PP (IN of) (NP (QP (IN up) (IN to) (CD 1)) (NN μM))) (PRN (-LRB- -LRB-) (NP (NP (NN stimulation)) (VP (VBG being) (ADJP-PRD (RB half) (HYPH -) (JJ maximal)) (PP (IN at) (NP (CD 0.1) (NNS μM))))) (-RRB- -RRB-)))) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ-2 (NN inhibition)) (VP (VBD was) (VP (VBN observed) (NP-2 (-NONE- *)) (PP (IN at) (NP (JJR higher) (NNS concentrations))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2D)) (-RRB- -RRB-)))))))) (. .)) )
( (S (ADVP (RB Importantly)) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (ADJP (RB maximally) (JJ inhibitory)) (NN tolbutamide) (NN concentration))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NNS mM)) (-RRB- -RRB-)))) (, ,) (NP-SBJ-1 (NN glucose)) (VP (VBD was) (ADJP-PRD (JJ unable) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB produce) (NP (NP (DT any) (JJ further) (NN inhibition)) (PP (IN of) (NP (NN glucagon) (NN release)))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3A)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (DT These) (NNS data)) (VP (VBP are) (ADJP-PRD (JJ inconsistent) (PP (IN with) (NP (DT the) (NN idea) (SBAR (IN that) (S (NP-SBJ (NML (NN β) (HYPH -) (NN cell)) (NN secretion)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ primary) (NN inhibitor)) (PP (IN of) (NP (NML (NN α) (HYPH -) (NN cell)) (NN glucagon) (NN release))))))))))) (. .)) )
( (S (NP-SBJ (PRP They)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN glucagon) (NN secretion)) (VP (VBZ is) (ADJP-PRD (JJ maximal)) (PP (IN within) (NP (NP (DT a) (`` “) (NN window)) ('' ”) (PP (IN of) (NP (JJ intermediate) (NML (NN KATP) (NN channel)) (NN activity))))))))) (. .)) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (ADVP (RB further)) (VP (VB investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NML (NN α) (HYPH -) (NN cell)) (NN KATP) (NNS channels))) (PP (IN as) (NP (NP (NNS regulators)) (PP (IN of) (NP (NN glucagon) (NN secretion))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD studied) (NP (NP (NNS islets)) (PP (IN from) (NP (NP (NN Kir6.2Y12X) (NNS mice)) (, ,) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ posses) (NP (NP (DT a) (NN Tyr12STOP) (NN mutation)) (PP-LOC (IN in) (NP (DT the) (NN Kcnj11) (NN gene)))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG leading) (PP (IN to) (NP (NP (JJ premature) (NN termination)) (PP (IN of) (NP (DT the) (NML (NN KATP) (NN channel)) (NML (NN pore) (HYPH -) (VBG forming)) (NN subunit))))))))))))) (PRN (-LRB- [) (NP (CD 48)) (-RRB- ]))) (. .)) )
( (S (PP (IN At) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NNS concentrations))) (, ,) (NP-SBJ-1 (NP (NN glucagon) (NN secretion)) (PP (IN from) (NP (DT the) (NN Kir6.2Y12X) (NNS islets)))) (VP (VBD was) (ADVP (RB already)) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN from) (NP (NML (JJ wild) (HYPH -) (NN type)) (NNS islets)))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3B)) (-RRB- -RRB-)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ similar) (PP (IN to) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN glucose) (NN stimulation)) (CC or) (NP (JJ pharmacological) (NML (NN KATP) (NN channel)) (NN inhibition))))) (VP (VBN observed) (NP (-NONE- *)) (PP (IN in) (NP (NNS Figures) (NML (NN 2D) (CC and) (NN 3A))))))))))) (. .)) )
( (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ Consistent) (PP (IN with) (NP (DT a) (JJ recent) (NN report))) (PRN (-LRB- [) (NP (CD 49)) (-RRB- ])))) (, ,) (NP-SBJ (JJR higher) (NN glucose) (NNS levels)) (VP (VBD stimulated) (NP (NN glucagon) (NN secretion)) (, ,) (PP-PRP (ADVP (RB perhaps)) (IN due) (IN to) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN of) (NP (NN metabolism))) (PP (IN on) (NP (NN secretion))))) (PRN (-LRB- [) (NP (CD 33)) (-RRB- ]))) (. .)) )
( (S (PP-LOC (IN In) (NP (NML (JJ wild) (HYPH -) (NN type)) (NNS islets))) (, ,) (S (S (NP-SBJ (NN glucagon) (NN secretion)) (VP (VBD exhibited) (NP (DT a) (NN nadir)) (PP (IN at) (NP (NML (CD 5) (NNS mM)) (NN glucose))))) (, ,) (CC and) (S (NP-SBJ (NP (NN glucagon) (NN secretion)) (PP (IN at) (NP (NML (CD 20) (NNS mM)) (NN glucose)))) (VP (VBD was) (ADJP-PRD (ADJP (NP (CD 40) (NN %)) (JJR higher)) (PP (IN than) (PP (IN at) (NP (NML (CD 5) (NNS mM)) (NN glucose)))))))) (. .)) )
( (S (NP-SBJ-2 (NP (NN Insulin) (NN secretion)) (PP-LOC (IN in) (NP (DT the) (NN Kir6.2Y12X) (NNS islets)))) (VP (VBD was) (VP (VBN elevated) (NP-2 (-NONE- *)) (PP (IN at) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NNS concentrations))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3C)) (-RRB- -RRB-)) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ-1 (ADJP (NN glucose) (HYPH -) (VBN stimulated)) (NN insulin) (NN secretion)) (VP (VBD was) (VP (VBN blunted) (NP-1 (-NONE- *)))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-2 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ notable)) (SBAR-2 (IN that) (S (NP-SBJ (NP (DT the) (NN increase)) (PP (IN in) (NP (NN glucagon) (NN release))) (PP (IN from) (NP (DT the) (NN Kir6.2Y12X) (NNS islets)))) (VP (VBD was) (ADJP-PRD (JJ coincident) (PP (IN with) (NP (VBN increased) (NN insulin) (NN secretion)))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG reinforcing) (NP (DT the) (NN view) (SBAR (IN that) (S (NP-SBJ-1 (NP (NN inhibition)) (PP (IN of) (NP (NN glucagon)))) (VP (VBZ is) (RB not) (VP (VBN mediated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT a) (NN factor)) (VP (VBN released) (NP (-NONE- *)) (PP-MNR (IN by) (NP (DT the) (NN β) (NNS cells))))))))))))))))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (PP-LOC (IN in) (NP (NN control) (NNS islets))) (, ,) (NP-SBJ (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN glucagon) (NN secretion)))) (VP (VBZ is) (ADJP-PRD (JJ maximal)) (PP (IN at) (NP (NP (NP (NP (DT a) (NN concentration)) (PP (IN of) (NP (NN glucose)))) (-LRB- -LRB-) (NP (CD 5) (NNS mM))) (-RRB- -RRB-) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ is) (PP-PRD (IN without) (NP (NP (JJ stimulatory) (NN action)) (PP (IN on) (NP (NN insulin) (NN secretion))))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP-TMP (RB next)) (VP (VBD examined) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NML (NN α) (CC and) (NN β)) (NNS cells)))) (ADVP (FW in) (FW situ)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG monitoring) (NP (NP (DT the) (NML (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (NNS responses)) (PP (IN of) (NP (JJ single) (NNS cells))) (PP-LOC (IN within) (NP (JJ intact) (NN mouse) (NNS islets)))))))) (. .)) )
( (S (NP-SBJ-1 (DT These)) (VP (VBD were) (ADVP (RB functionally)) (VP (VBN identified) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (PRP$ their) (NML (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (NN response)) (PP (IN to) (NP (NML (NML (CD 0.5) (, ,) (CD 2) (, ,) (CC and) (CD 11)) (NNS mM)) (NN glucose))))) (PRN (-LRB- [) (NP (CD 50)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (NN Glucose) (NN stimulation)) (VP (VBD suppressed) (NP (NP (DT the) (NML (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (NN response)) (PP (IN of) (NP (NN α) (NNS cells)))) (PP (IN by) (NP (QP (CD 51) (SYM ±) (CD 3)) (NN %) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (NP (CD 63) (NNS cells)) (PP-LOC (IN in) (NP (CD 15) (NNS islets)))))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-)))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 4A) (CC and) (NN 4B))) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (JJ suppressive) (NN effect)) (PP (IN of) (NP (NN glucose)))) (VP (VBD was) (VP (VBN alleviated) (NP-1 (-NONE- *)) (-LRB- -LRB-) (PP (IN to) (NP (NP (QP (CD 101) (SYM ±) (CD 11)) (NN %)) (PP (IN of) (NP (JJ initial) (NNS values))))) (-RRB- -RRB-) (PP-MNR (IN by) (NP (NP (NN application)) (PP (IN of) (NP (NML (CD 2) (NN μM)) (NN diazoxide))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 4A) (CC and) (NN 4B))) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ (NP (DT This) (NN concentration)) (PP (IN of) (NP (NN diazoxide)))) (VP (VBD was) (ADJP-PRD (ADJP (JJ similar) (PP (IN to) (NP (NP (DT that)) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD produced) (NP (NP (JJ maximal) (NN stimulation)) (PP (IN of) (NP (NN glucagon) (NN secretion)))))))))) (CC and) (ADJP (ADJP (JJ much) (PRN (-LRB- -LRB-) (ADVP (QP (SYM ∼) (RB 15-fold))) (-RRB- -RRB-)) (JJR lower)) (PP (IN than) (ADJP (JJ necessary) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB inhibit) (NP (NP (NN insulin) (NN secretion) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2B)) (-RRB- -RRB-))) (CC or) (NP (NP (NML (NN β) (HYPH -) (NN cell)) (NML (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (NNS responses)) (PP (IN to) (NP (NN glucose))))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 4A)) (-RRB- -RRB-)))) (. .)) )
( (HEADING (S (NP-SBJ (NN KATP) (NNS Channels)) (VP (VBP Regulate) (NP (JJ Human) (NML (NN α) (HYPH -) (NN Cell)) (NN Activity))))) )
( (S (NP-SBJ-1 (JJ Little) (NN work)) (VP (VBZ has) (VP (VBN been) (VP (VBN done) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (ADJP (NN glucose) (HYPH -) (VBN regulated)) (NN glucagon) (NN secretion)) (PP (IN from) (NP (VBN isolated) (JJ human) (NNS islets))))))))) (PRN (-LRB- [) (NP (CD 51)) (-RRB- ]))))) (. .)) )
( (S (NP-SBJ-1 (NP (NML (NN Glucagon) (CC and) (NN insulin)) (NN secretion)) (PP (IN from) (NP (NP (NNS islets)) (VP (VBN isolated) (NP (-NONE- *)) (PP (IN from) (NP (JJ healthy) (NNS donors))))))) (VP (VBD was) (VP (VBN examined) (NP-1 (-NONE- *)))) (. .)) )
( (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ Similar) (PP (IN to) (ADVP (RB above))))) (, ,) (NP-SBJ-1 (NP (NN glucagon) (NN secretion)) (PP (IN from) (NP (JJ human) (NNS islets)))) (VP (VBD was) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP-EXT (IN by) (NP (QP (CD 58) (SYM ±) (CD 3)) (NN %))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 9)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (-RRB- -RRB-)) (PP-TMP (IN upon) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG raising) (NP (DT the) (NN glucose) (NN concentration)) (PP (PP (IN from) (NP (CD 0) (NML-2 (-NONE- *RNR*)))) (PP (IN to) (NP (CD 10) (NML-2 (-NONE- *RNR*)))) (NML-2 (NNS mM)))))))) (. .)) )
( (S (NP-SBJ (NN Tolbutamide) (PRN (-LRB- -LRB-) (NP (CD 200) (NNS μM)) (-RRB- -RRB-))) (VP (VBD inhibited) (NP (NN glucagon) (NN release)) (PP (IN by) (NP (QP (CD 43) (SYM ±) (CD 14)) (NN %))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 7)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (-RRB- -RRB-))) (. .)) )
( (S (PP-TMP (IN At) (NP (DT the) (JJ same) (NN time))) (, ,) (NP-SBJ-1 (NN insulin) (NN secretion)) (VP (VBD was) (VP (VBN increased) (NP-1 (-NONE- *)) (ADVP-EXT (QP (CD 6.4) (HYPH -) (CC and) (RB 4.4-fold))) (PP-MNR (IN by) (NP (NML (NN glucose) (CC and) (NN tolbutamide)) (NN stimulation))) (, ,) (ADVP (RB respectively)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5A)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ (NP (JJ Moderate) (NN re-activation)) (PP (IN of) (NP (NN KATP) (NNS channels))) (PP (IN with) (NP (NML (CD 2) (NNS μM)) (NN diazoxide)))) (VP (VBD antagonized) (NP (NP (DT the) (ADJP (NN glucose) (HYPH -) (VBN induced)) (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN release)))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 7)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5B)) (-RRB- -RRB-))) (. .)) )
( (S (S (NP-SBJ (NP (DT A) (ADJP (RB 10-fold) (JJR higher)) (NN concentration)) (PP (IN of) (NP (NN diazoxide)))) (VP (VBD had) (NP (ADJP (RB significantly) (JJR less)) (JJ stimulatory) (NN effect)) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (CC versus) (NP (NML (CD 2) (NNS μM)) (NN diazoxide)) (-RRB- -RRB-)))) (, ,) (CC and) (S (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NML (CD 200) (NNS μM)) (NN diazoxide))))) (, ,) (NP-SBJ (NN glucagon) (NN secretion)) (VP (VBD was) (RB not) (ADJP-PRD (JJ different) (PP (IN from) (NP (NP (DT that)) (VP (VBN observed) (NP (-NONE- *)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT the) (NML (NN KATP) (NN channel)) (NN activator))))))))))) (. .)) )
( (S (ADVP (RB Importantly)) (, ,) (NP-SBJ (NP (NP (DT the) (JJS lowest) (NN concentration)) (PP (IN of) (NP (NN diazoxide)))) (PRN (-LRB- -LRB-) (NP (CD 2) (NNS μM)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD produced) (NP (NP (DT the) (JJS strongest) (NN stimulation)) (PP (IN of) (NP (NN glucagon) (NN secretion)))))))) (, ,) (VP (VBD had) (NP (NP (DT no) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (ADJP (NN glucose) (HYPH -) (VBN stimulated)) (NN insulin) (NN secretion))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 5)))) (-RRB- -RRB-))) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ (QP (CD 20) (CC and) (CD 200)) (NNS μM)) (VP (VBD produced) (NP (NP (ADJP (JJ partial) (CC or) (JJ complete)) (NN inhibition)) (PP (IN of) (NP (NN insulin) (NN secretion)))))))) (. .)) )
( (S (S (NP-SBJ (NP (DT The) (NN GABAA) (NN receptor) (NN antagonist)) (NP (NN SR95531))) (VP (VBD had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (ADJP (NN glucose) (HYPH -) (VBN induced)) (NN inhibition)) (PP (IN of) (NP (NN glucagon) (NN secretion))) (PP (IN from) (NP (JJ human) (NNS islets)))))))) (, ,) (CC and) (S (NP-SBJ (NML (JJ whole) (HYPH -) (NN cell)) (NML (NN voltage) (HYPH -) (NN clamp)) (NNS measurements)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (JJ human) (NN α) (NNS cells)) (, ,) (PP (IN unlike) (NP (JJ human) (NML (NN β) (CC and) (NN δ)) (NNS cells))) (, ,) (VP (VBP express) (NP (ADJP (JJ few) (PRN (SBAR (IN if) (FRAG (NP (DT any)))))) (NML (NN GABAA) (NN receptor)) (NML (NN Cl) (SYM −)) (NNS channels))))) (CIT (-LRB- -LRB-) (NNP M.) (NNP Braun) (, ,) (NNP R.) (NNP Ramracheya) (, ,) (CC and) (NNP P.) (NNP Rorsman) (, ,) (JJ unpublished) (NNS data) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ (NP (NN Examination)) (PP (IN of) (NP (NP (DT the) (NN Ca2+) (NNS responses)) (PP (IN of) (NP (JJ single) (NML (NN α) (CC and) (NN β)) (NNS cells))) (PP-LOC (IN within) (NP (JJ intact) (JJ human) (NNS islets)))))) (VP (VBD demonstrated) (SBAR (SBAR (IN that) (S (NP-SBJ (NN glucose)) (VP (VBD decreased) (NP (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (PP-EXT (IN by) (NP (QP (CD 62) (SYM ±) (CD 3)) (NN %))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (NP (CD 42) (NNS cells)) (PP-LOC (IN in) (NP (CD 7) (NNS islets)))))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-)) (PP-LOC (IN in) (NP (NN α) (NNS cells)))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ-1 (DT this) (NN effect)) (VP (MD could) (VP (VB be) (ADVP (RB completely)) (VP (VBN reversed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NML (CD 2) (NNS μM)) (NN diazoxide))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 6A) (CC and) (NN 6B))) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-1 (NP (DT the) (NN re-activation)) (PP (IN of) (NP (NML (NN α) (HYPH -) (NN cell)) (NML (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (NNS responses))) (PP (IN by) (NP (NN diazoxide)))) (VP (MD could) (VP (VB be) (VP (VBN prevented) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NN application)) (PP (IN of) (NP (NML (CD 100) (NNS μM)) (NN tolbutamide))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG confirming) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN KATP) (NNS channels)))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 6C)) (-RRB- -RRB-))))) (. .)) )
( (S (NP-SBJ (NP (DT An) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NML (NN dose) (HYPH –) (NN response)) (NN relationship)) (PP (IN to) (NP (NN diazoxide)))))) (VP (VBD demonstrated) (NP (NP (DT a) (ADJP (RB maximally) (JJ effective)) (NN concentration)) (PP (IN of) (NP (CD 1.7) (NNS μM))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 6D) (CC and) (NN 6E))) (: ;) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (NP (CD 38) (NNS cells)) (PP-LOC (IN in) (NP (CD 9) (NNS islets)))))) (-RRB- -RRB-)) (, ,) (PP (ADVP (RB far)) (IN below) (NP (NP (DT the) (NN concentration)) (ADJP (JJ necessary) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB block) (NP (NML (NN β) (HYPH -) (NN cell)) (NNS responses))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 6D)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (NNS Increases)) (PP (IN in) (NP (NN diazoxide))) (PP (IN above) (NP (CD 20) (NNS μM)))) (VP (VBD blocked) (NP (NP (DT the) (NML (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (NNS responses)) (PP (IN of) (NP (NP (NN α) (NNS cells)) (CC and) (NP (NN β) (NNS cells))))) (PP (IN in) (NP (JJ parallel))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (NP (DT the) (NN effect)) (PP (IN on) (NP (NML (NN glucagon) (CC and) (NN insulin)) (NN release)))))))) (. .)) )
( (HEADING (S (NP-SBJ (NN Na+) (NNS Channels)) (VP (VBP Regulate) (NP (ADJP (NP (JJ Low) (HYPH -) (NN Glucose)) (HYPH –) (VBN Stimulated)) (NN Glucagon) (NN Secretion))))) )
( (S (NP-SBJ (DT The) (JJ above) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-1 (NP (ADJP (NN glucose) (HYPH -) (JJ dependent)) (NN inhibition)) (PP (IN of) (NP (NML (NN α) (HYPH -) (NN cell)) (NN KATP) (NNS channels)))) (VP (VBZ is) (VP (VBN involved) (NP-1 (-NONE- *)) (PP (IN in) (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN secretion)))))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (RB not) (ADJP-PRD (JJ clear)) (ADVP (RB however)) (, ,) (SBAR-1 (WHADVP-2 (WRB how)) (S (NP-SBJ (NP (NML (NN KATP) (NN channel)) (NN inhibition)) (CC and) (NP (NN membrane) (NN depolarisation))) (VP (VBP result) (PP (IN in) (NP (NP (NN suppression)) (PP (IN of) (NP (NN secretion))))) (ADVP-MNR-2 (-NONE- *T*)))))) (. .)) )
( (S (PP (IN Unlike) (PP-LOC (IN in) (NP (NN β) (NNS cells)))) (, ,) (NP-SBJ (NML (NN α) (HYPH -) (NN cell)) (NN Na+) (NNS channels)) (VP (VBP are) (ADJP-PRD (JJ active) (PP (IN in) (NP (NP (DT the) (JJ physiological) (NN range)) (PP (IN of) (NP (NN membrane) (NNS potentials))))))) (. .)) )
( (S (NP-SBJ (NP (JJ Previous) (NN work)) (PP (IN from) (NP (PRP$ our) (NN group)))) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ (NP (NP (DT the) (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation)) (PP (IN of) (NP (NN Na+) (NNS channels)))) (, ,) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (PP-LOC (IN in) (NP (NN mouse) (NN α) (NNS cells))) (VP (VBZ is) (ADJP-PRD (RB half) (HYPH -) (JJ maximal)) (PP (IN at) (NP (QP (SYM −) (CD 42)) (NNS mV)))))) (PRN (-LRB- [) (NP (CD 43)) (-RRB- ]))) (, ,) (VP (VBZ contributes) (PP (IN to) (NP (NP (NN cessation)) (PP (IN of) (NP (JJ electrical) (NN activity))))) (PP-MNR (IN upon) (NP (NML (NN α) (HYPH -) (NN cell)) (NN depolarisation)))))) (PRN (-LRB- [) (NP (CD 14)) (-RRB- ]))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB thus)) (VP (VBD used) (NP (NP (DT the) (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NML (NML (NN Na+) (NN channel)) (NN antagonist))) (NP (NP (NN tetrodotoxin)) (-LRB- -LRB-) (NP (NN TTX)))) (-RRB- -RRB-) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB test) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (DT these) (NNS channels))) (PP (IN in) (NP (NP (NML (NN α) (HYPH -) (NN cell)) (NN function)) (CC and) (NP (NN glucagon) (NN secretion))))))))) (. .)) )
( (S (NP-SBJ (NN TTX) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (NNS μg)) (PP (SYM /) (NP (NN ml)))) (-RRB- -RRB-))) (VP (VBD suppressed) (NP (NN glucagon) (NN release)) (PP (IN from) (NP (NN mouse) (NNS islets))) (PP-EXT (IN by) (NP (QP (CD 56) (SYM ±) (CD 5)) (NN %))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 10)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-)) (PP (IN under) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NNS conditions))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 7A)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (DT This) (NN effect)) (PP (IN of) (NP (NN TTX))) (PP (IN in) (NP (DT the) (NML (JJ low) (HYPH -) (NN glucose)) (NN condition)))) (VP (VBD was) (ADJP-PRD (JJ similar) (PP (IN to) (SBAR-NOM (WHNP-1 (WP what)) (S (NP-SBJ (PRP we)) (VP (VBD observed) (NP-1 (-NONE- *T*)) (PP (IN with) (NP (NP (NML (JJ high) (HYPH -) (NN glucose)) (NN stimulation)) (ADVP (RB alone)))))))))) (. .)) )
( (S (SBAR-ADV (IN With) (S (NP-SBJ (NN TTX)) (ADJP-PRD (NN present)))) (, ,) (NP-SBJ (NN glucose)) (VP (VBD was) (PP-PRD (IN without) (NP (JJ further) (JJ inhibitory) (NN action))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN glucose)) (VP (VBZ inhibits) (NP (NN glucagon) (NN secretion)) (PP-MNR (IN through) (NP (DT a) (ADJP (NP (NN Na+) (NN channel)) (HYPH -) (JJ dependent)) (NN mechanism))))))))) (. .)) )
( (S (NP-SBJ (NN TTX)) (VP (VBZ has) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (ADJP (NN glucose) (HYPH -) (VBN stimulated)) (NN insulin) (NN secretion)))) (PP-LOC (IN in) (NP (NN mouse) (NNS islets))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 7A)) (-RRB- -RRB-)) (: ;) (S-ADV (ADVP (RB again)) (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ suggestive) (PP (IN of) (NP (NP (DT a) (ADJP (JJ direct) (CONJP (RB rather) (IN than)) (JJ indirect)) (NN effect)) (PP (IN on) (NP (NN α) (NNS cells)))))))) (. .)) )
( (S (PP (IN In) (NP (NP (NN accordance)) (PP (IN with) (NP (DT this))))) (, ,) (NP-SBJ (NP (NN application)) (PP (IN of) (NP (NML (NP (CD 0.1) (NNS μg)) (PP (SYM /) (NP (NN ml)))) (NN TTX))) (PP (IN to) (NP (NN mouse) (NNS islets)))) (VP (VP (ADVP (RB reversibly)) (VBD abolished) (NP (NP (DT the) (NML (NN α) (HYPH -) (NN cell)) (NML (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (NN response)) (VP (VBN evoked) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NNS concentrations))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 7B) (CC and) (NN 7C))) (: ;) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 18) (NNS cells)) (PP-LOC (IN in) (NP (CD 4) (NNS islets))))) (-RRB- -RRB-))) (, ,) (CC but) (VP (VBD had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NML (NN β) (HYPH -) (NN cell)) (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i))))) (CIT (-LRB- -LRB-) (JJ unpublished) (NNS data) (-RRB- -RRB-))) (. .)) )
( (HEADING (S (NP-SBJ (NML (NN N) (HYPH -) (NN Type)) (NN Ca2+) (NNS Channels)) (VP (VBP Mediate) (NP (NP (DT the) (NN Ca2+) (NN Influx)) (SBAR (WHNP-1 (WDT That)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ Triggers) (NP (NP (NN Glucagon) (NN Secretion)) (CC and) (NP (NML (NN α) (HYPH -) (NN Cell)) (NN Exocytosis)))))))))) )
( (S (ADVP (RB Downstream) (PP (IN of) (NP (NML (NN Na+) (NN channel)) (NN activation)))) (, ,) (NP-SBJ (NP (DT the) (NN opening)) (PP (IN of) (NP (NNS VDCCs)))) (VP (VBZ allows) (NP (NN Ca2+)) (PP (IN into) (NP (NN α) (NNS cells))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG triggering) (NP (NP (DT the) (NN exocytosis)) (PP (IN of) (NP (ADJP (NN glucagon) (HYPH -) (VBG containing)) (NNS vesicles))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD applied) (NP (NML (JJ whole) (HYPH -) (NN cell)) (NML (NN patch) (HYPH -) (NN clamp)) (NNS recordings)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB establish) (NP (DT the) (NML (NN α) (HYPH -) (NN cell)) (NML (NN Ca2+) (NN channel)) (NN complement)))))) (. .)) )
( (S (S (NP-SBJ (NP (DT The) (JJ integrated) (NML (JJ whole) (HYPH -) (NN cell)) (NN Ca2+) (NN current)) (VP (VBN measured) (NP (-NONE- *)) (PP-TMP (IN during) (NP (NP (NML (CD 50) (HYPH -) (NN ms)) (NNS depolarisations)) (PP (PP (IN from) (NP (QP (SYM −) (CD 70)) (NNS mV))) (PP (IN to) (NP (CD 0) (NNS mV)))))))) (VP (VBD amounted) (PP (IN to) (NP=1 (QP (CD 6.2) (SYM ±) (CD 0.8)) (NN pC) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 15)))) (-RRB- -RRB-))) (PP=2 (IN under) (NP (NN control) (NNS conditions)))))) (, ,) (S (NP=1 (QP (CD 2.6) (SYM ±) (CD 0.8)) (NN pC) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 10)))) (: ;) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (-RRB- -RRB-))) (PP=2 (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NML (CD 50) (NNS μM)) (NN nifedipine)))))) (, ,) (CC and) (S (NP=1 (QP (CD 4.1) (SYM ±) (CD 0.5)) (NN pC) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 12)))) (: ;) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (-RRB- -RRB-))) (PP=2 (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NML (CD 1) (NN μM)) (NN ω) (HYPH -) (NN conotoxin)))))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NML (NML (NN L) (HYPH -) (CC and) (NN N)) (HYPH -) (NN type)) (NN Ca2+) (NNS channels)) (VP (VBP account) (PP (IN for) (NP (NP (NP (CD 58) (NN %)) (CC and) (NP (CD 34) (NN %))) (PP (IN of) (NP (DT the) (NML (NN α) (HYPH -) (NN cell)) (NN Ca2+) (NN current))))) (, ,) (ADVP (RB respectively))) (. .)) )
( (S (NP-SBJ (NN Figure) (NN 8A)) (VP (VBZ compares) (NP (NN glucagon) (NN secretion)) (PP (IN at) (NP (NML (NML (CD 1) (CC and) (CD 20)) (NNS mM)) (NN glucose))) (PP (PP (IN under) (NP (NN control) (NNS conditions))) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NML (CD 100) (NNS nM)) (NN ω) (HYPH -) (NN conotoxin)) (CC and) (NP (NML (CD 20) (NNS μM)) (NN nifedipine))))))) (, ,) (ADVP (RB respectively))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD found) (SBAR (IN that) (S (SBAR-ADV (IN whereas) (S (NP-SBJ (NP (DT the) (NML (NN L) (HYPH -) (NN type)) (NN channel) (NN blocker)) (NP (NN nifedipine))) (VP (VBD had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN glucagon) (NN release)))) (PP (IN at) (NP (NML (NML (CD 1) (CC or) (CD 20)) (NNS mM)) (NN glucose)))))) (, ,) (NP-SBJ (NP (DT the) (NML (NN N) (HYPH -) (NN type)) (NML (NN Ca2+) (NN channel)) (NN blocker)) (NP (NN ω) (HYPH -) (NN conotoxin))) (VP (VBD inhibited) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (DT the) (NN hormone)))) (PP (IN to) (NP (NP (DT a) (NN level)) (ADJP (JJ similar) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ high) (NN glucose)) (, ,) (NP (NN tolbutamide)) (, ,) (CC and) (NP (NN TTX))))))))))))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NN glucose)) (VP (VBD exerted) (NP (DT no) (JJ additional) (JJ inhibitory) (NN action)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN ω) (HYPH -) (NN conotoxin)))))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (NN glucagon) (NN secretion)) (VP (VBN stimulated) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NNS levels))))) (VP (VBZ depends) (ADVP (RB principally)) (PP (IN on) (NP (NN Ca2+) (NN influx))) (PP (IN through) (NP (NML (NN N) (HYPH -) (NN type)) (NNS channels))) (, ,) (SBAR-ADV (IN although) (S (NP-SBJ (DT these)) (ADVP (RB only)) (VP (VBP account) (PP (IN for) (NP (NP (CD one) (NN third)) (PP (IN of) (NP (DT the) (NN Ca2+) (NN current))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD confirmed) (NP (DT this) (NML (NN Ca2+) (NN channel)) (NN dependence)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG conducting) (NP (NP (NML (JJ high) (HYPH -) (NN resolution)) (NML (JJ single) (HYPH -) (NN cell)) (NN capacitance) (NNS measurements)) (PP (IN of) (NP (NN exocytosis))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 8B)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (NN Exocytosis)) (VP (VBN elicited) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NP (NML (CD 500) (HYPH -) (NN ms)) (NN step) (NNS depolarisations)) (PP (PP (IN from) (NP (QP (SYM −) (CD 70)) (NML-1 (-NONE- *RNR*)))) (PP (IN to) (NP (CD 0) (NML-1 (-NONE- *RNR*)))) (NML-1 (NNS mV))))))) (VP (VBD averaged) (NP (QP (RB approximately) (CD 150)) (NNS fF)) (-LRB- -LRB-) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG corresponding) (PP (IN to) (NP (NP (DT the) (NN fusion)) (PP (IN of) (NP (QP (SYM ∼) (CD 75)) (JJ secretory) (NNS granules))) (PP (IN with) (NP (DT the) (NN plasma) (NN membrane))) (PRN (-LRB- [) (NP (CD 43)) (-RRB- ])) (-RRB- -RRB-) (PP (IN under) (NP (NP (NN control) (NNS conditions)) (-LRB- -LRB-) (NP (NN Ctrl))))))))) (-RRB- -RRB-) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN response)) (VP (VP (VBD was) (RB not) (ADVP (RB significantly)) (VP (VBN affected) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NML (CD 50) (NN μM)) (NN nifedipine) (PRN (-LRB- -LRB-) (NP (NN nif)) (-RRB- -RRB-)))))) (, ,) (CC but) (VP (VBD was) (ADVP (RB nearly)) (VP (VBN abolished) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NML (CD 1) (NN μM)) (NN ω) (HYPH -) (NN conotoxin)) (PRN (-LRB- -LRB-) (NP (NN ω) (HYPH -) (NN con)) (: ;) (NP (NN Figure) (NN 8C)) (-RRB- -RRB-)))))) (. .)) )
( (HEADING (S (NP-SBJ (NP (NN Inactivation)) (PP (IN of) (NP (NML (NN N) (HYPH -) (NN Type)) (NN Ca2+) (NNS Channels)))) (VP (VBP Underlie) (NP (NP (NN Glucose) (NN Inhibition)) (PP (IN of) (NP (NN Glucagon) (NN Secretion))))))) )
( (S (NP-SBJ (PRP We)) (ADVP (RB next)) (VP (VBD examined) (NP (NP (DT the) (NN mechanism)) (SBAR (WHPP-1 (IN by) (WHNP (WDT which))) (S (NP-SBJ (NML (NN N) (HYPH -) (NN type)) (NNS channels)) (VP (VBP regulate) (NP (NN glucagon) (NN release)) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NN membrane) (NML (NN depolarisation) (HYPH /) (NN hyperpolarisation)))))) (PP-LOC (IN in) (NP (NN mouse) (NN α) (NNS cells))) (PP-MNR-1 (-NONE- *T*))))))) (. .)) )
( (S (NP-SBJ-1 (NML (JJ Non–L) (HYPH -) (NN type)) (PRN (-LRB- -LRB-) (ADJP (NN isradipine) (HYPH -) (JJ resistant)) (-RRB- -RRB-)) (NN Ca2+) (NNS currents)) (VP (VBD were) (VP (VBN elicited) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NN step) (NN depolarization)) (PP (IN to) (NP (CD 0) (NNS mV))))) (PP (IN in) (NP (NP (DT the) (NML (NML (NN absence) (PRN (-LRB- -LRB-) (ADJP (JJ black)) (-RRB- -RRB-))) (CC or) (NML (NN presence) (PRN (-LRB- -LRB-) (ADJP (JJ red)) (-RRB- -RRB-))))) (PP (IN of) (NP (NML (CD 1) (NN μM)) (NN ω) (HYPH -) (NN conotoxin))))) (PP (IN following) (NP (NP (DT a) (NML (CD 200) (HYPH -) (NN ms)) (NN conditioning) (NN pulse)) (PP (IN to) (NP (NP (QP (SYM −) (CD 70)) (NNS mV) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 9A)) (-RRB- -RRB-))) (CC or) (NP (QP (SYM +) (CD 10)) (NNS mV) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 9B)) (-RRB- -RRB-))))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ evident)) (SBAR-1 (IN that) (S (NP-SBJ-2 (DT the) (ADJP (NP (NN ω) (HYPH -) (NN conotoxin)) (HYPH –) (JJ sensitive)) (NN component)) (VP (VBD was) (VP (VBN abolished) (NP-2 (-NONE- *)) (PP-MNR (IN by) (NP (DT the) (NML (QP (SYM +) (CD 10)) (NN mV)) (NN conditioning) (NN pulse)))))))) (. .)) )
( (S (NP-SBJ (NN Figure) (NN 9C)) (VP (VBZ summarizes) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (DT the) (NN conditioning) (NN voltage)) (CC and) (NP (DT the) (NN Ca2+) (NN current) (NN amplitude)))) (PP (IN in) (NP (NP (DT the) (NML (NN absence) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS squares)) (-RRB- -RRB-)) (CC and) (NN presence) (PRN (-LRB- -LRB-) (NP (NNS circles)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN ω) (HYPH -) (NN conotoxin)))))) (PRN (-LRB- -LRB-) (NP (JJ upper) (NN panel)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ-1 (DT The) (ADJP (NP (NN ω) (HYPH -) (NN conotoxin)) (HYPH –) (JJ sensitive)) (NML (NN N) (HYPH -) (NN type)) (NN Ca2+) (NN current) (NN component)) (VP (VP (VBZ is) (VP (VBN shown) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (JJR lower) (NN panel)) (PP (IN of) (NP (NN Figure) (NN 9C))))))) (, ,) (CC and) (VP (VBD underwent) (NP (NP (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBD was) (ADJP-PRD (RB half) (HYPH -) (JJ maximal) (PRN (-LRB- -LRB-) (NP (NN V0.5)) (-RRB- -RRB-))) (PP (IN at) (NP (QP (SYM −) (CD 31) (SYM ±) (CD 6)) (NNS mV))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 6)))) (-RRB- -RRB-)))))))) (. .)) )
( (S (NP-SBJ-1 (DT A) (JJ residual) (, ,) (ADJP (NP (NN ω) (HYPH -) (NN conotoxin)) (HYPH –) (JJ insensitive)) (NN Ca2+) (NN current)) (ADVP (RB also)) (VP (VBZ appears) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB undergo) (NP (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 9C)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VP (VBZ accounts) (PP (IN for) (NP (NP (QP (JJR less) (IN than) (CD 15)) (NN %)) (PP (IN of) (NP (DT the) (VBG inactivating) (NN current)))))) (, ,) (CC and) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ attributable) (PP (IN to) (NP (NP (NML (NN T) (HYPH -) (NN type)) (NN Ca2+) (NNS channels)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN α) (NNS cells))))))))))))) (PRN (-LRB- [) (NP (CD 14)) (-RRB- ]))) (. .)) )
( (S (PP (IN In) (NP (NN Figure) (NN 9D))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (DT the) (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN activation)) (PP (IN of) (NP (NML (NN α) (HYPH -) (NN cell)) (NN exocytosis)))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (ADJP (NN step) (HYPH -) (JJ wise)) (NNS depolarisations) (PRN (-LRB- -LRB-) (NP (CD 500) (NNS ms)) (-RRB- -RRB-))) (PP (PP (IN from) (NP (QP (SYM −) (CD 70)) (NNS mV))) (PP (IN to) (NP (QP (IN between) (SYM −) (CD 50) (CC and) (CD 20)) (NNS mV))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 9D)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (DT The) (NML (NML (NN capacitance) (NN response)) (CC versus) (NML (NN voltage))) (NN relationship) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 9E)) (-RRB- -RRB-))) (VP (VBZ demonstrates) (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN capacitance) (NN response)) (PP (IN between) (NP (QP (SYM −) (CD 10) (CC and) (CD 10)) (NNS mV))))))) (. .)) )
( (S (ADVP (RB Thus)) (NP-SBJ (NP (DT any) (NN reduction)) (PP (IN in) (NP (NN action) (NN potential) (NN amplitude))) (PP (IN within) (NP (DT this) (NN range)))) (VP (MD would) (ADVP (RB severely)) (VP (VB attenuate) (NP (NML (NN α) (HYPH -) (NN cell)) (NN exocytosis)))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation)) (PP (IN of) (NP (NML (NN α) (HYPH -) (NN cell)) (NN exocytosis)))) (VP (VBD was) (VP (VBN examined) (NP-1 (-NONE- *)) (ADVP (RB next)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 9F)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (NNS Cells)) (VP (VBD were) (VP (VBN held) (NP-1 (-NONE- *)) (PP (IN at) (NP (NP (NN conditioning) (NNS potentials)) (PP (IN between) (NP (NML (NML (SYM −) (CD 70)) (CC and) (NML (SYM −) (CD 30))) (NNS mV))))) (, ,) (SBAR-TMP (WHPP-3 (IN after) (WHNP (WDT which))) (S (NP-SBJ-2 (NN exocytosis)) (VP (VBD was) (VP (VBN elicited) (NP-2 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NN depolarisation)) (PP (IN to) (NP (CD 0) (NNS mV))))) (PP-TMP-3 (-NONE- *T*)))))))) (. .)) )
( (S (NP-SBJ (NP (NN Exocytosis)) (VP (VBN stimulated) (NP (-NONE- *)) (PP (IN from) (NP (DT the) (NML (QP (SYM −) (CD 30)) (NN mV)) (NN conditioning) (NN potential))))) (VP (VBD was) (NP-PRD (NP (RB only) (CD 25) (NN %)) (PP (IN of) (NP (NP (DT that)) (VP (VBN elicited) (NP (-NONE- *)) (PP (IN from) (NP (QP (SYM −) (CD 70)) (NN mV))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 9G)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (DT This) (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN decline)) (PP-TMP (IN in) (NP (NN exocytosis)))) (VP (VBZ is) (ADJP-PRD (JJ attributable) (PP (IN to) (NP (NP (DT the) (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation)) (PP (IN of) (NP (DT the) (NML (NN N) (HYPH -) (NN type)) (NN Ca2+) (NNS channels))))))) (. .)) )
( (S (NP-SBJ-2 (DT The) (NN fact) (SBAR (IN that) (S (NP-SBJ-1 (NP (NN inhibition)) (PP (IN of) (NP (NN exocytosis)))) (VP (VBZ appears) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB occur) (PP (IN at) (NP (NP (ADJP (RB more) (HYPH -) (JJ negative)) (NNS voltages)) (PP (IN than) (NP (NP (DT that)) (VP (VBN documented) (NP (-NONE- *)) (PP (IN for) (NP (NP (DT the) (NN inactivation)) (PP (IN of) (NP (DT the) (NML (NN N) (HYPH -) (NN type)) (NN Ca2+) (NNS channels))))))))))))))))) (VP (MD can) (VP (VB be) (VP (VBN attributed) (NP-2 (-NONE- *)) (PP (IN to) (NP (NP (NP (DT the) (NN brevity)) (PP (IN of) (NP (DT the) (NN conditioning) (NNS pulses))) (PP (IN in) (NP (NN Figure) (NML (NML (NN 9A)) (PP (SYM –) (NP (NN 9C))))))) (-LRB- -LRB-) (NP (CD 200) (NNS ms)) (-RRB- -RRB-))) (, ,) (SBAR-ADV (IN whereas) (S (PP (IN in) (NP (NN Figure) (NN 9G))) (NP-SBJ (DT the) (NN holding) (NN potential)) (VP (VBD was) (ADJP-PRD (JJ varied)))))))) (. .)) )
( (HEADING (NP (NN Discussion))) )
( (S (NP-SBJ (NP (VBN Regulated) (NN glucagon) (NN secretion)) (PP (IN from) (NP (JJ pancreatic) (NN α) (NNS cells)))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ major) (NN component)) (PP (IN of) (NP (NP (DT the) (JJ counter-regulatory) (NN response)) (PP (IN to) (NP (NN hypoglycaemia))))))) (. .)) )
( (S (NP-SBJ-1 (NN Diabetes) (NN mellitus)) (VP (VBZ is) (ADJP-PRD (JJ associated) (PP (IN with) (NP (NP (NP (NNS defects)) (PP (IN of) (NP (NN glucagon) (NN secretion)))) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP exacerbate) (NP (NP (DT the) (NNS consequences)) (PP (IN of) (NP (JJ impaired) (NN insulin) (NN secretion)))))))))) (PRN (-LRB- [) (NP (NP (CD 2)) (PP (SYM –) (NP (CD 4)))) (-RRB- ]))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NN mechanism)) (VP (VBG regulating) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (DT this) (JJ important) (NN hormone)))))) (VP (VBZ is) (UCP-PRD (VP (ADVP (RB incompletely)) (VBN understood) (NP-1 (-NONE- *))) (CC and) (NP (ADVP-TMP (RB currently)) (NP (DT the) (NN source)) (PP (IN of) (NP (JJ much) (NN debate)))))) (. .)) )
( (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (NP (NN glucagon) (NN secretion)) (CC and) (NP (NP (DT the) (NML (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (NN response)) (PP (IN of) (NP (ADJP (FW in) (FW situ)) (NN α) (NNS cells))))) (PP (IN of) (NP (VBN isolated) (UCP (NN rodent) (CC and) (JJ human)) (NNS islets))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB further)) (VP (VBD characterised) (NP (NP (DT the) (NN Ca2+) (NML (NML (NNS currents)) (CC and) (NML (NN capacitance) (NNS changes)))) (PP (IN of) (NP (JJ single) (JJ isolated) (NN α) (NNS cells)))) (, ,) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB dissect) (NP (NP (DT the) (NN mechanism)) (VP (VBG regulating) (NP (NP (JJ downstream) (NN control)) (PP (IN of) (NP (NN glucagon) (NN release)))))))))) (. .)) )
( (S (NP-SBJ (NP (JJ Previous) (NN work)) (PP (IN with) (NP (JJ genetic) (NN mouse) (NNS models))) (, ,) (PP (VBG including) (NP (NML (NML (NN SUR1) (SYM −) (HYPH /) (SYM −) (PRN (-LRB- [) (NP (CD 13) (, ,) (CD 34) (, ,) (CD 35)) (-RRB- ]))) (CC and) (NML (NN Kir6.2) (SYM −) (HYPH /) (SYM −) (PRN (-LRB- [) (NP (CD 16)) (-RRB- ])))) (NNS mice)))) (, ,) (VP (VBZ suggests) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN for) (NP (NN KATP) (NNS channels))) (PP (IN in) (NP (NN glucagon) (NN secretion))))) (. .)) )
( (S (NP-SBJ (NP (CD Three) (NNS pieces)) (PP (IN of) (NP (NN evidence)))) (VP (VBP argue) (PP-PRP (IN for) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NN islet) (NN KATP) (NNS channels))) (PP (IN in) (NP (NN glucagon) (NN secretion)))))) (. .)) )
( (S (ADVP (RB First)) (, ,) (NP-SBJ (NP (NN introduction)) (PP (IN of) (NP (DT the) (NN Tyr12STOP) (NN mutation))) (PP-LOC (IN into) (NP (NP (DT the) (NML (NN KATP) (NN channel)) (NNS subunits)) (PP-LOC (IN in) (NP (DT the) (NN Kir6.2Y12X) (NNS islets)))))) (VP (VP (VBZ results) (PP (IN in) (NP (NP (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN secretion))) (PP (IN at) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NNS levels)))))) (CC and) (VP (VBZ causes) (NP (NP (NN loss)) (PP (IN of) (NP (NP (NML (NN glucose) (HYPH -) (VBN induced)) (NN inhibition)) (PP (IN of) (NP (NN secretion)))))))) (. .)) )
( (S (ADVP (RB Second)) (, ,) (NP-SBJ (NP (NP (DT the) (NML (NN KATP) (NN channel)) (NN inhibitor)) (NP (NN tolbutamide))) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN applied) (NP-1 (-NONE- *)) (PP (IN at) (NP (ADJP (RB maximally) (JJ effective)) (NNS concentrations))) (ADVP-TMP-2 (-NONE- *T*)))))) (VP (VBZ inhibits) (NP (NN glucagon) (NN secretion)) (PP (IN from) (NP (VBN isolated) (NNS islets)))) (. .)) )
( (S (ADVP (RB Third)) (, ,) (NP-SBJ (NP (DT a) (JJ low) (NN dose)) (PP (IN of) (NP (NP (DT the) (NML (NN KATP) (NN channel)) (NN activator)) (NP (NN diazoxide))))) (VP (VBZ restores) (NP (NP (NML (NN α) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses)) (CC and) (NP (NN glucagon) (NN secretion))) (PP (IN in) (NP (NML (JJ high) (HYPH -) (NN glucose)) (NNS conditions)))) (. .)) )
( (S (SBAR-NOM-SBJ (WHNP-1 (WDT What)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ is) (RB not) (ADVP (RB immediately)) (ADJP-PRD (JJ clear) (PP (PP (IN from) (NP (DT these) (NNS arguments))) (, ,) (CC and) (PP (IN from) (NP (DT the) (JJ previous) (NML (NN SUR1) (SYM −) (HYPH /) (SYM −)) (JJ genetic) (NNS studies)))))))) (, ,) (VP (VBZ is) (SBAR-NOM-PRD (IN whether) (S (NP-SBJ-2 (NN glucagon)) (VP (VBZ is) (VP (VBG being) (VP (VBN controlled) (NP-2 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT the) (NML (NN α) (HYPH -) (NN cell)) (NML-3 (-NONE- *RNR*))) (CC or) (NP (DT the) (NML (NN β) (HYPH -) (NN cell)) (NML-3 (-NONE- *RNR*))) (NML-3 (NN KATP) (NNS channels)))) (, ,) (SBAR-ADV (IN as) (S (NP-SBJ (DT the) (JJ latter)) (VP (MD may) (VP (VB regulate) (NP (NML (NN α) (HYPH -) (NN cell)) (NN function)) (ADVP (RB indirectly)) (PP-MNR (IN via) (NP (JJ paracrine) (NNS pathways))))))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB therefore)) (VP (VBD examined) (NP (NP (NML (NN insulin) (CC and) (NN glucagon)) (NN secretion)) (, ,) (CC and) (NP (NP (DT the) (NN Ca2+) (NNS responses)) (PP (IN of) (NP (NML (NN α) (CC and) (NN β)) (NNS cells))))) (ADVP (FW in) (FW situ)) (PP (IN in) (NP (NN parallel))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ functional) (NN relationship)) (PP (IN between) (NP (DT these) (NNS cells)))))))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBD measured) (NP (NP (DT the) (NN glucagon) (NN response)) (PP (IN to) (NP (NN glucose)))) (PP-TMP (IN during) (NP (NP (NN blockade)) (PP (IN of) (NP (JJ putative) (JJ paracrine) (NN signalling) (NNS pathways)))))) (. .)) )
( (S (NP-SBJ (NP (NNS Studies)) (PP (IN on) (NP (NN rat) (NNS islets)))) (VP (VBP support) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN for) (NP (NP (JJ paracrine) (NNS signals)) (PP (IN as) (NP (NP (NNS regulators)) (PP (IN of) (NP (NN glucagon) (NN release))))))) (PRN (-LRB- [) (CD 33) (, ,) (CD 52) (, ,) (CD 53) (-RRB- ]))) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ (NP (DT the) (NN case)) (PP (IN for) (NP (NP (JJ paracrine) (NN regulation)) (PP (IN of) (NP (NP (NN glucagon) (NN secretion)) (PP (IN from) (NP (UCP (NN mouse) (CC and) (JJ human)) (NN α) (NNS cells)))))))) (VP (VBZ is) (ADJP-PRD (RBR less) (JJ clear))))) (PRN (-LRB- [) (NP (NP (CD 9)) (, ,) (NP (CD 10)) (, ,) (NP (CD 14)) (, ,) (NP (NP (CD 17)) (PP (SYM –) (NP (CD 21)))) (, ,) (NP (CD 27))) (-RRB- ]))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ clear)) (SBAR-1 (IN that) (S (NP-SBJ (NN Zn2+) (, ,) (NN GABA) (, ,) (CC and) (NN somatostatin)) (VP (MD can) (VP (VB exert) (NP (NP (DT a) (JJ paracrine) (NN control)) (PP (IN of) (NP (NN glucagon) (NN secretion)))) (PP (IN under) (NP (JJ certain) (NNS conditions)))))))))) (, ,) (NP-SBJ (NP (DT the) (NNS data)) (VP (VBN shown) (NP (-NONE- *)) (ADVP (RB here)))) (ADVP (RB firmly)) (VP (VB establish) (SBAR (DT that) (S (NP-SBJ (NN glucose)) (VP (MD can) (VP (VB suppress) (NP (NN glucagon) (NN secretion)) (ADVP (RB independently) (PP (IN of) (NP (DT these) (NNS pathways)))) (SBAR-ADV (IN as) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN demonstrated) (NP-2 (-NONE- *)) (PP (PP (IN in) (NP (NN Figure) (CD 1))) (-LRB- -LRB-) (CC and) (PP (IN in) (-LRB- [) (NP (CD 47)))))))))))) (-RRB- ]) (-RRB- -RRB-) (. .)) )
( (S (UCP (ADVP (RB Furthermore)) (, ,) (CC and) (PP (IN in) (NP (NP (NN agreement)) (PP (IN with) (NP (ADJP (RB recently) (VBN published)) (NNS results))))) (PRN (-LRB- [) (NP (CD 47)) (-RRB- ]))) (, ,) (NP-SBJ (NP (JJ maximal) (NN inhibition)) (PP (IN of) (NP (NN glucagon) (NN release)))) (VP (VBZ occurs) (PP (IN at) (NP (NP (NNS levels)) (ADJP (ADJP (JJ equal) (PP (IN to) (NP-1 (-NONE- *RNR*)))) (CC or) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP-1 (-NONE- *RNR*)))) (NP-1 (NML (CD 5) (NN mM)) (NN glucose))))) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NN insulin) (NN release)))) (VP (VBZ requires) (NP (NP (NN glucose) (NNS levels)) (ADJP (JJR greater) (PP (IN than) (NP (CD 5) (NNS mM))) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 3)) (-RRB- -RRB-))))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ-2 (NP (NNS products)) (PP (IN of) (NP (NML (NN β) (HYPH -) (NN cell)) (NN secretion)))) (VP (VBP are) (RB not) (VP (VBN required) (NP-2 (-NONE- *)) (PP-PRP (IN for) (NP (NP (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN release)))))))))))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN conclusion)) (VP (VBZ is) (ADVP (RB further)) (VP (VBN underpinned) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NP (DT the) (JJ significant) (NN discordance)) (PP (IN between) (NP (NML (NN insulin) (CC and) (NN glucagon)) (NN release)))) (, ,) (CC and) (NP (DT the) (NML (NML (NN β) (HYPH -) (CC and) (NN α)) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses)))) (, ,) (PP (IN under) (NP (NP (JJ several) (NNS conditions)) (: :) (UCP (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NP (DT the) (NML (NN KATP) (NN channel)) (NN opener)) (NP (NN diazoxide))))) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP stimulate) (NP (NN glucagon) (NN secretion)) (SBAR-ADV (IN while) (S (NP-SBJ (-NONE- *PRO*)) (VP (RB not) (VBG affecting) (NP (NN insulin) (NN release))))))))) (: ;) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN diazoxide)))) (SBAR (WHPP-4 (IN at) (WHNP (WDT which))) (S (NP-SBJ-3 (NP (NN suppression)) (PP (IN of) (NP (NML (NN β) (HYPH -) (NN cell)) (NN secretion)))) (VP (MD would) (VP (VB be) (VP (VBN expected) (NP-3 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB elevate) (NP (NN glucagon) (NN release))))) (PP-4 (-NONE- *T*)))))))) (: ;) (PP-LOC (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (IN in) (NP (DT the) (NN Kir6.2Y12X) (NNS islets))) (: ;) (CC and) (PP (LST (-LRB- -LRB-) (LS 4) (-RRB- -RRB-)) (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NP (DT the) (NML (NN Na+) (NN channel)) (NN blocker)) (NP (NN TTX))))))))))) (. .)) )
( (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (PRP$ our) (NNS data)) (VP (VBP argue) (SBAR (IN that) (S (NP-SBJ (ADJP (NN glucagon) (HYPH -) (VBG producing)) (NN α) (NNS cells)) (VP (VBP possess) (NP (NP (DT an) (JJ intrinsic) (NN mechanism)) (UCP (PP (IN for) (NP (NP (NN regulation)) (PP (IN by) (NP (NN glucose))))) (CC and) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ involves) (NP (NN KATP) (NNS channels))))))))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VBZ is) (PP-PRD (PP (IN at) (NP (NP (NN variance)) (PP (IN with) (NP (NP (DT the) (NNS data)) (PP (IN of) (NP (NP (NP (NNP Liu)) (ADVP-ETC (FW et) (FW al.))) (PRN (-LRB- [) (NP (CD 12)) (-RRB- ])) (SBAR (WHNP-1 (WP who)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (NN tolbutamide)) (VP (VBZ has) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)))) (PP-LOC (IN in) (NP (JJ single) (, ,) (VBN isolated) (NN α) (NNS cells))))))))))))))) (, ,) (CC but) (PP (IN in) (NP (NP (NN agreement)) (PP (IN with) (NP (NP (DT the) (NN conclusion) (SBAR-2 (-NONE- *ICH*))) (PP (IN of) (NP (NP (NNP Ostenson)) (ADVP-ETC (FW et) (FW al.))) (PRN (-LRB- [) (NP (CD 54)) (-RRB- ]))) (, ,) (SBAR-2 (IN that) (S (NP-SBJ (NNS sulfonylureas)) (VP (MD can) (VP (VB inhibit) (NP (NN glucagon) (NN secretion)) (PP-MNR (IN by) (NP (DT a) (JJ direct) (, ,) (JJ non-paracrine) (NN mechanism))))))))))))) (. .)) )
( (S (PP (IN On) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (PRP$ our) (NNS findings))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (NML (NN α) (HYPH -) (NN cell)) (NN glucagon) (NN secretion)) (VP (VBZ occurs) (PP (IN within) (NP (NP (DT a) (JJ narrow) (NN window)) (PP (IN of) (NP (NP (JJ intermediate) (NML (NN KATP) (NN channel)) (NN activity)) (-LRB- -LRB-) (CC and) (NP (ADVP (RB thus)) (NN membrane) (NN potential))))))))) (-RRB- -RRB-) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 10)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB That) (RB is)) (, ,) (SBAR-ADV (IN if) (S (NP-SBJ (DT the) (NN α) (NN cell)) (VP (VBZ is) (ADJP-PRD (DT either) (ADJP (RB too) (VBN hyperpolarised) (PRN (-LRB- -LRB-) (NP (JJ maximal) (NN KATP) (NN activity)) (-RRB- -RRB-))) (CC or) (ADJP (RB too) (VBN depolarised) (PRN (-LRB- -LRB-) (NP (JJ maximal) (NN KATP) (NN inhibition)) (-RRB- -RRB-))))))) (, ,) (ADVP (RB then)) (NP-SBJ-1 (NN glucagon) (NN secretion)) (VP (VBZ is) (VP (VBN suppressed) (NP-1 (-NONE- *)))) (. .)) )
( (S (NP-SBJ-1 (DT This)) (VP (VBZ is) (VP (VBN supported) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT the) (JJ biphasic) (NNS effects)) (PP (IN of) (NP (CC both) (NN diazoxide) (CC and) (NN tolbutamide))))))) (. .)) )
( (S (SBAR-ADV (IN Whereas) (S (NP-SBJ (DT the) (JJ former) (PRN (-LRB- -LRB-) (PP (IN in) (NP (JJ high) (NN glucose))) (-RRB- -RRB-))) (VP (VBZ brings) (NP (DT the) (NN α) (NN cell)) (PP-MNR (IN in) (NP (DT a) (ADJP (NN dose) (HYPH -) (JJ dependent)) (NN manner))) (PP (IN through) (NP (NP (DT the) (NN membrane) (NN potential) (NN window)) (VP (VBG supporting) (NP (NN glucagon) (NN secretion)) (PP (IN in) (NP (DT the) (NML (NML (VBN depolarised) (PRN (-LRB- -LRB-) (NP (JJ low) (NN KATP)) (-RRB- -RRB-))) (PP (IN to) (NP (VBN hyperpolarised) (PRN (-LRB- -LRB-) (NP (JJ high) (NN KATP)) (-RRB- -RRB-))))) (NN direction))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 10C)) (-RRB- -RRB-)))))))) (, ,) (NP-SBJ (DT the) (JJ latter) (PRN (-LRB- -LRB-) (PP (IN in) (NP (CD zero) (NN glucose))) (-RRB- -RRB-))) (VP (VBZ brings) (NP (DT the) (NN α) (NN cell)) (PP (IN through) (NP (DT the) (NN window))) (PP (IN in) (NP (DT the) (JJ opposite) (NN direction)) (PRN (-LRB- -LRB-) (PP (PP (IN from) (ADJP (VBN hyperpolarised))) (PP (IN to) (ADJP (VBN depolarised)))) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 10B)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NN glucose)) (ADVP (RB likely)) (VP (VBZ leads) (PP (IN to) (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN secretion))))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG depolarising) (NP (DT the) (NML (NN α) (HYPH -) (NN cell)) (NN membrane) (NN potential)) (PP (IN above) (NP (NP (DT the) (NN range)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ supports) (NP (NN glucagon) (NN secretion)))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 10A)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Indeed)) (, ,) (PP (IN in) (NP (NP (DT some) (NML-1 (-NONE- *RNR*))) (-LRB- -LRB-) (CONJP (CC but) (RB not)) (NP (DT all) (NML-1 (-NONE- *RNR*))) (, ,) (PRN (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VBP see) (-LRB- [) (NP (CD 55))) (-RRB- ]) (-RRB- -RRB-))) (NML-1 (NNS studies)))) (, ,) (NP-SBJ-2 (NN glucose)) (VP (VBD was) (VP (VBN found) (S (NP-SBJ-2 (-NONE- *)) (VP (TO to) (VP (VP (VB depolarize) (NP (NML (NN mouse) (CC and) (NN rat)) (NN α) (NNS cells))) (CC and) (VP (VB reduce) (NP (NN action) (JJ potential) (NNS amplitudes)))))) (PRN (-LRB- [) (NP (CD 13) (, ,) (CD 52)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ interesting)) (SBAR-1 (IN that) (S (SBAR-ADV (IN whereas) (S (NP-SBJ (NP (JJ low) (NNS concentrations)) (PP (IN of) (NP (NN glucose)))) (VP (VBD were) (PP-PRD (IN without) (NP (JJ stimulatory) (NN effect)))))) (, ,) (NP-SBJ (NN tolbutamide) (PRN (-LRB- -LRB-) (NP (QP (CD 0.1) (SYM –) (CD 1)) (NNS μM)) (-RRB- -RRB-))) (VP (VBD stimulated) (NP (NN glucagon) (NN release)) (PP (IN beyond) (NP (NP (DT that)) (VP (VBN observed) (NP (-NONE- *)) (PP (IN at) (NP (CD zero) (NN glucose)))))))))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (JJ small) (NNS depolarisations) (PRN (-LRB- -LRB-) (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (ADVP (RB previously)) (VP (VBN documented) (NP-1 (-NONE- *)) (PP (IN for) (NP (NN arginine) (-LRB- [) (CD 13))))) (-RRB- ]) (-RRB- -RRB-)))) (VP (VP (VBP exert) (NP (DT a) (JJ positive) (`` “) (JJ chronotropic) ('' ”) (NN effect)) (PP-LOC (IN in) (NP (NN α) (NNS cells)))) (CC and) (VP (ADVP (RB thus)) (VBP stimulate) (NP (NN glucagon) (NN release)))) (. .)) )
( (S (NP-SBJ (DT The) (NN fact) (SBAR (IN that) (S (NP-SBJ (NN glucose)) (VP (VBD did) (RB not) (VP (VB share) (NP (DT this) (NN ability))))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN depolarisation)) (VP (VBN produced) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NML (CD 1) (NN mM)) (NN glucose))))) (VP (VBZ results) (PP (IN in) (NP (NP (NP (JJ sufficient) (NN inactivation)) (PP (IN of) (NP (DT the) (NNS currents)))) (SBAR (WHADVP-1 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB balance) (NP (NP (DT any) (NN increase)) (PP (IN in) (NP (NN action) (NN potential) (NN frequency)))) (ADVP-MNR-1 (-NONE- *T*)))))))))))) (. .)) )
( (S (NP-SBJ (JJ Previous) (JJ human) (NNS studies)) (VP (VBP have) (VP (VBN employed) (NP (JJ pharmacological) (NML (NN KATP) (NN channel)) (NML (NNS antagonists) (PRN (-LRB- [) (NP (CD 23) (, ,) (CD 24)) (-RRB- ])) (CC or) (NNS agonists)) (PRN (-LRB- [) (NP (CD 25) (, ,) (CD 26)) (-RRB- ]))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN glucagon) (NN release)))) (ADVP (FW in) (FW vivo))))))) (. .)) )
( (S (NP-SBJ-1 (DT These)) (VP (VBD were) (VP (VBN interpreted) (NP-1 (-NONE- *)) (PP (IN with) (NP (DT the) (NN assumption) (SBAR (SBAR (IN that) (S (NP-SBJ (JJ pharmacological) (NN KATP) (NN modulation)) (ADVP (RB only)) (VP (VBZ affects) (NP (DT the) (NN β) (NNS cells))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ (NP (DT any) (NN change)) (PP (IN in) (NP (NN glucagon) (NN release)))) (VP (VBD was) (ADVP (RB therefore)) (ADJP-PRD (JJ secondary) (PP (IN to) (NP (JJ altered) (NML (NN β) (HYPH -) (NN cell)) (NN function)))))))))))) (. .)) )
( (S (NP-SBJ (PRP$ Our) (NNS data)) (VP (VBP establish) (SBAR (IN that) (S (NP-SBJ (NML (NN KATP) (NN channel)) (NN modulation)) (VP (VBZ has) (NP (NP (ADJP (JJ dramatic) (CC and) (JJ direct)) (NNS effects)) (PP (IN on) (NP (NP (NP (NN glucagon) (NN secretion)) (CC and) (NP (NN Ca2+) (NN signalling))) (PP-LOC (IN in) (NP (JJ human) (NN α) (NNS cells)))))) (PP (IN under) (NP (NP (NNS conditions)) (SBAR (WHPP-1 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NN insulin) (NN secretion)) (VP (VBZ is) (ADJP-PRD (JJ unaffected)) (PP-1 (-NONE- *T*))))))))))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (DT the) (ADJP (FW in) (FW vivo)) (NN manipulation)) (PP (IN of) (NP (NML (NN α) (HYPH -) (NN cell)) (NML (NN KATP) (NN channel)) (NN activity))) (PP (IN in) (NP (DT the) (JJ above) (NNS studies)))) (VP (MD may) (ADVP (RB well)) (VP (VB have) (VP (VBN involved) (NP (NP (NP (JJ direct) (NNS effects)) (PP (IN on) (NP (NML (NN α) (HYPH -) (NN cell)) (NN function)))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD contributed) (PP (IN to) (NP (NP (DT the) (VBN observed) (NNS changes)) (PP (IN in) (NP (NN glucagon) (NN release)))))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NN importance)) (PP (IN of) (NP (DT the) (JJ human) (NML (NN KATP) (NN channel)) (NN pathway))) (PP (IN for) (NP (NN glucagon) (NN release)))) (VP (VBZ is) (ADVP (RB nicely)) (VP (VBN highlighted) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT a) (NN study)) (VP (VBG investigating) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ common) (NN Glu23Lys) (PRN (-LRB- -LRB-) (NP (NN E23K)) (-RRB- -RRB-)) (NN polymorphism)) (PP (IN of) (NP (NP (DT the) (NN Kir6.2) (NN subunit)) (PP (IN of) (NP (DT the) (NN KATP) (NN channel))))))) (PP (IN on) (NP (NP (NML (NN insulin) (CC and) (NN glucagon)) (NN secretion)) (PP-LOC (IN in) (NP (JJ non-diabetic) (JJ human) (NNS patients))))))))) (PRN (-LRB- [) (NP (CD 29)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (NP (DT This) (NN variant)) (PP (IN of) (NP (DT the) (NN channel)))) (VP (VBZ leads) (PP (IN to) (NP (NP (DT a) (JJ slight) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN ATP) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN channel)))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (JJ functional) (NN significance)) (PP (IN of) (NP (DT this)))) (VP (VBD was) (VP (VBN examined) (NP-1 (-NONE- *)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG comparing) (NP (NN hormone) (NN release)) (PP-TMP (IN during) (NP (NP (JJ hyperglycaemic) (NNS clamps)) (PP-LOC (IN in) (NP (NP (NNS individuals)) (VP (VP (VBG carrying) (NP (DT the) (NN polymorphism))) (CC or) (VP (FRAG (RB not))))))))))))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ (NP (NN insulin) (NN secretion)) (PP-LOC (IN in) (NP (JJ homozygous) (NN Glu23Lys) (NNS individuals)))) (VP (VBD was) (RB not) (ADJP-PRD (JJ different) (PP (IN from) (NP (NNS controls))))))) (, ,) (NP-SBJ-1 (NP (ADJP (NN glucose) (HYPH -) (VBN induced)) (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN release)))) (VP (VBD was) (VP (VBN blunted) (NP-1 (-NONE- *)) (PRN (-LRB- [) (NP (CD 29)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VBZ becomes) (ADJP-PRD (JJ understandable)) (PP (IN in) (NP (NP (NN light)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN diazoxide))) (PP (IN on) (NP (VBN isolated) (JJ human) (NNS islets))))))) (PRN (-LRB- -LRB-) (NP (NNS Figures) (NML (CD 4) (CC and) (CD 5))) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (ADJP (RB Half) (HYPH -) (JJ maximal)) (NN activation)) (PP (IN of) (NP (NN KATP) (NNS channels)))) (VP (VBZ occurs) (PP (IN at) (NP (NP (NN diazoxide) (NNS concentrations)) (PP (IN of) (NP (QP (CD 20) (SYM –) (CD 100)) (NNS μM))))) (-LRB- -LRB-) (PP (IN depending) (PP (IN on) (NP (DT the) (JJ intracellular) (NN ATP) (NN level)))) (-RRB- -RRB-) (PRN (-LRB- [) (NP (CD 56)) (-RRB- ]))) (. .)) )
( (S (SBAR-PRP (IN If) (S (NP-SBJ (DT the) (NN Glu23Lys) (NN polymorphism)) (VP (VBZ increases) (NP (NML (NN KATP) (NN channel)) (NN activity)) (PP (IN to) (NP (NP (DT the) (JJ same) (NN extent)) (PP (IN as) (NP (NP (NML (QP (CD 0.3) (HYPH –) (CD 1.5)) (NNS μM)) (NN diazoxide)) (, ,) (NP (NP (DT the) (NN concentration)) (SBAR (WHPP-2 (IN at) (WHNP (WDT which))) (S (NP-SBJ-1 (NP (DT an) (NN effect)) (PP (IN on) (NP (NN glucagon) (NN release)))) (VP (VBZ is) (ADVP (RB first)) (VP (VBN seen) (NP-1 (-NONE- *)) (PP-2 (-NONE- *T*)))))))))))))) (, ,) (ADVP (RB then)) (NP-SBJ (DT the) (NN effect)) (VP (MD will) (VP (VB be) (ADJP-PRD (RB very) (JJ difficult) (SBAR (WHNP-6 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB detect) (NP-6 (-NONE- *T*)) (PP-MNR (IN with) (NP (NN electrophysiology)))))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADVP (RB perhaps)) (VP (VBG explaining) (SBAR-PRP (WHADVP-4 (WRB why)) (S (NP-SBJ-3 (DT some) (NNS studies)) (VP (VBP have) (VP (VBN failed) (S (NP-SBJ-3 (-NONE- *)) (VP (TO to) (VP (VB detect) (NP (NP (DT a) (JJ functional) (NN effect)) (PP (IN of) (NP (DT the) (NN polymorphism))))))) (ADVP-PRP-4 (-NONE- *T*)))))))) (PRN (-LRB- -LRB-) (S (NP-SBJ-5 (-NONE- *PRO*)) (VP (VBN reviewed) (NP-5 (-NONE- *)) (PP (IN in) (NP (-LRB- [) (CD 57))))) (-RRB- ]) (-RRB- -RRB-)))) (. .)) )
( (S (ADVP (RB Nevertheless)) (, ,) (NP-SBJ (JJ such) (JJ small) (NNS changes)) (VP (VP (MD can) (VP (VB have) (NP (JJ significant) (JJ biological) (NNS effects)) (, ,) (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN illustrated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (DT the) (NML (NN glucagon) (NN release)) (NNS data)))))))) (, ,) (CC and) (VP (MD may) (VP (VB contribute) (PP (IN to) (NP (NP (JJ pathological) (NNS states)) (PP (JJ such) (IN as) (NP (NP (VBN impaired) (NN glucose) (NN tolerance)) (CC and) (NP (NN diabetes))))))))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (DT the) (VBN reduced) (NN ability) (S-1 (-NONE- *ICH*))) (PP (IN of) (NP (NN glucose))) (S-1 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB inhibit) (NP (NN glucagon) (NN secretion)) (PP-LOC (IN in) (NP (NP (NNS individuals)) (VP (VBG carrying) (NP (NP (DT the) (NN Glu23Lys) (NN variant)) (PP (IN of) (NP (DT the) (NN KATP) (NN channel))))))))))) (ADVP (RB likely)) (VP (VBZ results) (PP (IN from) (NP (NP (DT the) (NN failure) (S-2 (-NONE- *ICH*))) (PP (IN of) (NP (DT these) (NNS channels))) (S-2 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB undergo) (NP (JJ complete) (NN inhibition)) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NN glucose))))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN proposed) (SBAR (SBAR (IN that) (S (NP-SBJ-1 (NN glucagon) (NN secretion)) (VP (VBZ is) (VP (VBN stimulated) (NP-1 (-NONE- *)) (PP (IN within) (NP (NP (DT a) (NN window)) (PP (IN of) (NP (JJ intermediate) (NML (NN α) (HYPH -) (NN cell)) (NML (NN KATP) (NN channel)) (NN activity))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ-2 (NN glucagon) (NN release)) (VP (VBZ is) (VP (VBN suppressed) (NP-2 (-NONE- *)) (PP-MNR (IN by) (NP (NP (CC either) (NML (NNS increases) (CC or) (NNS decreases))) (PP (IN in) (NP (NML (NN KATP) (NN channel)) (NN activity)))))))))))) (. .)) )
( (SBARQ (WHADVP-1 (WRB How)) (SQ (VBZ is) (NP-SBJ-2 (DT this)) (VP (VBN accomplished) (NP-2 (-NONE- *)) (ADVP-MNR-1 (-NONE- *T*)))) (. ?)) )
( (S (ADVP (RB Briefly)) (, ,) (NP-SBJ (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (DT this) (NN window)) (VP (VBZ is) (NP-PRD (NP (DT the) (NN result)) (PP (IN of) (NP (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (DT the) (NN ability) (S-6 (-NONE- *ICH*))) (PP (IN of) (NP (JJ intermediate) (NML (NN KATP) (NN channel)) (NN activity))) (S-6 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB support) (NP (JJ regenerative) (JJ electrical) (NNS responses)) (PP-MNR (IN through) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NML (NML (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN Na+)) (CC and) (NML (NML (NN N) (HYPH -) (NN type)) (NN Ca2+))) (NNS channels))))) (PRN (-LRB- -LRB-) (ADJP (JJ grey)) (PP (IN in) (NP (NN Figure) (CD 10))) (-RRB- -RRB-)))))) (: ;) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (DT the) (NN failure) (S-7 (-NONE- *ICH*))) (PP (IN of) (NP (DT the) (NML (NN Na+) (CC and) (NN Ca2+)) (NNS channels))) (S-7 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB activate) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (NN α) (NNS cells)) (VP (VBP are) (VP (VBN hyperpolarised) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT the) (NN opening)) (PP (IN of) (NP (NP (DT a) (JJ major) (NN fraction)) (PP (IN of) (NP (NN KATP) (NNS channels))))))) (ADVP-TMP-2 (-NONE- *T*)) (PRN (-LRB- -LRB-) (PP (IN above) (NP (NP (DT the) (NN grey)) (PP (IN in) (NP (NN Figure) (CD 10))))) (-RRB- -RRB-)))))))))) (: ;) (CC and) (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (NP (DT the) (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation)) (PP (IN of) (NP (DT the) (NML (NML (NN Na+) (PRN (-LRB- [) (NP (CD 14)) (-RRB- ]))) (CC and) (NML (NN N) (HYPH -) (NN type))) (NN Ca2+) (NNS channels)))) (SBAR (WHADVP-5 (WRB when)) (S (S (S (NP-SBJ-3 (NN KATP) (NNS channels)) (VP (VBP are) (VP (VBN closed) (NP-3 (-NONE- *))))) (CC and) (S (NP-SBJ-4 (DT the) (NML (NN α) (HYPH -) (NN cell)) (NN membrane) (NN potential)) (VP (VBZ is) (VP (VBN depolarised) (NP-4 (-NONE- *)))))) (ADVP-TMP-5 (-NONE- *T*)) (PRN (-LRB- -LRB-) (PP (IN below) (NP (NP (DT the) (NN grey)) (PP (IN in) (NP (NN Figure) (CD 10))))) (-RRB- -RRB-)))))))))))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (DT the) (JJ differential) (NN responsiveness)) (PP (IN of) (NP (NML (NN α) (CC and) (NN β)) (NNS cells))) (PP (IN to) (NP (NN diazoxide)))) (VP (VBZ does) (RB not) (VP (VB result) (PP (PP (IN from) (NP (NP (JJ differential) (NNS sensitivities)) (PP (IN of) (NP (NP (DT the) (NN KATP) (NNS channels)) (PP-LOC (IN in) (NP (DT these) (NNS cells))))))) (, ,) (CC but) (PP (IN to) (NP (NP (DT the) (JJ downstream) (NNS responses)) (PP (IN to) (NP (VBN titrated) (NML (NN KATP) (NN channel)) (NN activity)))))))) (. .)) )
( (S (NP-SBJ (NP (CD One) (JJ important) (NN difference)) (PP (IN between) (NP (NN mouse) (NML (NN α) (CC and) (NN β)) (NNS cells)))) (VP (VBZ is) (SBAR-PRD (IN that) (S (SBAR-ADV (IN whereas) (S (NP-SBJ (DT the) (JJ latter)) (VP (VBP rely) (ADVP (RB exclusively)) (PP (IN on) (NP (ADJP (NN voltage) (HYPH -) (VBN gated)) (NN Ca2+) (NNS channels))) (PP-PRP (IN for) (NP (NP (DT the) (NN upstroke)) (PP (IN of) (NP (DT the) (NN action) (NNS potentials)))))))) (, ,) (NP-SBJ-1 (NML (NN glucagon) (HYPH -) (VBG producing)) (NN α) (NNS cells)) (VP (VBP are) (VP (VBN equipped) (NP-1 (-NONE- *)) (PP (IN with) (NP (ADJP (NN voltage) (HYPH -) (VBN gated)) (NN Na+) (NNS channels)))))))) (. .)) )
( (S (NP-SBJ (DT These) (NNS channels)) (VP (VBP undergo) (NP (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation)) (PP (IN at) (NP (NP (NNS voltages)) (ADJP (ADJP (RBR more) (JJ positive)) (PP (IN than) (NP (QP (SYM −) (CD 50)) (NNS mV)))))) (PRN (-LRB- [) (NP (CD 14)) (-RRB- ]))) (. .)) )
( (S (S (NP-SBJ (DT This)) (VP (MD will) (VP (VB reduce) (NP (DT the) (NML (NN action) (NN potential)) (NN amplitude))))) (, ,) (CC and) (S (ADVP (RB indeed)) (NP-SBJ-1 (NP (PRP it)) (SBAR-2 (-NONE- *EXP*))) (VP (VBZ is) (VP (VBN reported) (NP-1 (-NONE- *)) (SBAR-2 (IN that) (S (NP-SBJ (NN glucose)) (VP (VBZ reduces) (NP (DT the) (JJ peak) (NN voltage)) (PP-LOC (IN in) (NP (NN α) (NNS cells))) (PP (PP (IN from) (NP (QP (SYM +) (CD 11)) (NNS mV))) (PP (IN to) (NP (QP (SYM −) (CD 1)) (NNS mV))))))) (PRN (-LRB- [) (NP (CD 13)) (-RRB- ]))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (MD will) (PP (IN in) (NP (PRP itself))) (VP (VB result) (PP (IN in) (NP (NP (DT an) (NML (QP (RB approximately) (CD 35)) (NN %)) (NN reduction)) (PP (IN of) (NP (NP (NN exocytosis)) (, ,) (SBAR (WHNP-2 (WDT which)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBZ is) (ADJP-PRD (RB steeply) (JJ dependent) (PP (IN on) (NP (NP (NN voltage)) (PP (IN between) (NP (QP (QP (SYM −) (CD 10)) (CC and) (QP (SYM +) (CD 10))) (NNS mV))))))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 9E)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (JJ functional) (NN significance)) (PP (IN of) (NP (DT this)))) (VP (VBZ is) (VP (VBN illustrated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (DT the) (NNS observations) (SBAR (IN that) (S (NP-SBJ-2 (NP (NP (NN glucagon) (NN secretion)) (CC and) (NP (NML (NN α) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses))) (PP (IN at) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NNS concentrations)))) (VP (VBP are) (VP (VBN suppressed) (NP-2 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT the) (NML (NN Na+) (NN channel)) (NN blocker)) (NP (NN TTX)))))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (JJ exact) (NML (NN ion) (NN channel)) (NN complement)) (PP (IN of) (NP (JJ human) (NN α) (NNS cells)))) (VP (VBZ remains) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB be) (VP (VBN established) (NP-1 (-NONE- *))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (DT the) (NN fact) (SBAR (IN that) (S (NP-SBJ (NP (NN glucagon) (NN secretion)) (PP (IN from) (NP (JJ human) (NNS islets)))) (VP (VBZ shows) (NP (NP (DT the) (JJ same) (ADJP (NN bell) (HYPH -) (VBN shaped)) (NML (NN diazoxide) (NN concentration)) (NN dependence)) (PP (IN as) (PP-LOC (IN in) (NP (NN mouse) (NNS islets))))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (ADJP (NN depolarization) (HYPH -) (VBN induced)) (NN inactivation)) (PP (IN of) (NP (NP (NN ion) (NNS channels)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (NML (NN α) (HYPH -) (NN cell)) (JJ regenerative) (JJ electrical) (NN activity))))))) (VP (VBZ underlies) (NP (NP (ADJP (NN glucose) (HYPH -) (VBN induced)) (NN suppression)) (PP (IN of) (NP (NN glucagon) (NN secretion)))) (PP-LOC (IN in) (NP (NN man))) (ADVP (RB as) (RB well)))))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ (NML (NN L) (HYPH -) (NN type)) (NNS VDCCs)) (VP (VBP mediate) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NN Ca2+) (NN current)))) (PP-LOC (IN in) (NP (NN α) (NNS cells)))))) (, ,) (NP-SBJ (NP (DT this) (NN work)) (CC and) (NP (JJ previous) (NNS studies)) (PRN (-LRB- [) (NP (CD 33) (, ,) (CD 44) (, ,) (CD 45)) (-RRB- ]))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (PRP it)) (VP (VBZ is) (NP-PRD (NP (DT the) (NML (NN N) (HYPH -) (NN type) (PRN (-LRB- -LRB-) (ADJP (NP (NN ω) (HYPH -) (NN conotoxin)) (HYPH –) (JJ sensitive)) (-RRB- -RRB-))) (NNS VDCCs)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP mediate) (NP (NP (DT the) (NN Ca2+) (NN influx)) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NP (NML (NN α) (HYPH -) (NN cell)) (NN exocytosis)) (CC and) (NP (NN glucagon) (NN secretion))) (PP (IN under) (NP (JJ hypoglycaemic) (NNS conditions))))))))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB now)) (VP (VBP show) (SBAR (SBAR (IN that) (S (NP-SBJ (DT the) (NML (NN α) (HYPH -) (NN cell)) (NML (NN N) (HYPH -) (NN type)) (NNS VDCCs)) (VP (VBP are) (ADVP (RB also)) (ADJP-PRD (JJ subject) (PP (IN to) (NP (NP (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation)) (PP (IN at) (NP (NP (NNS voltages)) (ADJP (ADJP (RBR more) (JJ positive)) (PP (IN than) (NP (QP (SYM −) (CD 50)) (NNS mV)))))))))))) (CC and) (SBAR (ADVP (RB furthermore)) (IN that) (S (NP-SBJ-1 (DT this)) (VP (VBZ is) (VP (VBN associated) (NP-1 (-NONE- *)) (PP (IN with) (NP (VBN reduced) (JJ exocytotic) (NN capacity))))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ pertinent)) (SBAR-1 (IN that) (S (NP-SBJ (NML (NN N) (HYPH -) (NN type)) (ADJP (NN VDCC) (HYPH -) (JJ deficient)) (NNS mice)) (VP (VBP exhibit) (NP (NP (VBN reduced) (NN serum) (NN glucagon) (NNS levels)) (CC and) (NP (VBN improved) (NN glucose) (NN tolerance))) (PP (IN despite) (NP (NP (DT a) (JJ parallel) (NN reduction)) (PP (IN in) (NP (NN plasma) (NN insulin)))))))) (PRN (-LRB- [) (NP (CD 44)) (-RRB- ]))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ-1 (NP (NN Ca2+) (NN influx)) (PP (IN through) (NP (NML (NN L) (HYPH -) (NN type)) (NN Ca2+) (NNS channels)))) (VP (VBZ does) (RB not) (VP (VB appear) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB contribute) (NP (RB much)) (PP (IN to) (NP (NN glucagon) (NN secretion))) (PP (IN under) (NP (NP (DT the) (JJ experimental) (NNS conditions)) (VP (VBN used) (NP (-NONE- *)) (PP (IN in) (NP (DT this) (NN study))))))))))))) (, ,) (NP-SBJ (DT these) (NNS channels)) (VP (VBP become) (NP-PRD (NP (DT the) (JJ predominant) (NN conduit)) (PP (IN of) (NP (NN Ca2+) (NN entry))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNS agents)) (VP (VBG increasing) (NP (NN cAMP)))))))) (PRN (-LRB- [) (NP (CD 41)) (-RRB- ])) (CIT (-LRB- -LRB-) (JJ unpublished) (NNS data) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN mechanism)) (VP (VBG underlying) (NP (NP (DT this) (NN switch)) (PP (IN in) (NP (NML (NN Ca2+) (NN channel)) (NN dependence)))))) (VP (VP (VBZ remains) (ADJP-PRD (JJ obscure))) (, ,) (CC but) (VP (MD may) (VP (VB depend) (PP (IN on) (NP (NP (DT the) (NN strength)) (PP (IN of) (NP (NN depolarisation))))) (SBAR-PRP (IN because) (S (NP-SBJ-1 (NP (NN glucagon) (NN secretion)) (VP (VBN stimulated) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NP (JJ strong) (NN depolarisation)) (PP (IN with) (NP (VBN increased) (NN K+))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NML (NN KATP) (NN channel)) (NN block))))))))) (VP (MD can) (VP (VB be) (VP (VBN prevented) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NML (NN L) (HYPH -) (NN type)) (NN Ca2+) (NNS channels)))))))))))) (PRN (-LRB- [) (NP (CD 47)) (-RRB- ]))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB finally)) (VP (VBP point) (PRT (RP out)) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN model)) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ (PRP we)) (VP (VBP propose) (NP-1 (-NONE- *T*)) (ADVP (RB here)) (PP-PRP (IN for) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NN glucagon) (NN secretion))))))))) (VP (VBZ shares) (NP (JJ many) (NNS features)) (PP (IN with) (SBAR-NOM (WHNP-2 (WP what)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBZ is) (VP (VBN known) (NP-2 (-NONE- *)) (PP (IN about) (NP (NP (DT the) (JJ metabolic) (NN control)) (PP (IN of) (NP (NN insulin) (NN secretion)))))))))))))) (. .)) )
( (S (NP-SBJ (DT This)) (PP (IN in) (NP (NN turn))) (VP (VBZ means) (SBAR (IN that) (S (NP-SBJ (NP (NNS processes)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP interfere) (PP (IN with) (NP (NP (DT the) (NN ability) (S-2 (-NONE- *ICH*))) (PP (IN of) (PRN (, ,) (PP (IN for) (NP (NN example))) (, ,)) (NP (NN glucose))) (S-2 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB stimulate) (NP (NN insulin) (NN secretion))))))))))) (VP (MD will) (VP (VB have) (NP (NP (DT the) (JJ opposite) (NN effect)) (PP (IN on) (NP (NN glucagon) (NN secretion))))))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (MD would) (VP (VB provide) (NP (NP (DT a) (JJ simple) (NN explanation)) (PP (IN for) (NP (NP (DT the) (NN fact) (SBAR (IN that) (S (NP-SBJ (CC both) (NML (NN insulin) (CC and) (NN glucagon)) (NN secretion)) (VP (VBD become) (ADJP-PRD (VBN perturbed)) (PP (IN in) (NP (NN diabetes))))))) (CC and) (SBAR-NOM (WHADVP-1 (WRB why)) (S (NP-SBJ (NP (NN oversecretion)) (PP (IN of) (NP (NN glucagon)))) (VP (VBZ exacerbates) (NP (NP (DT the) (JJ hyperglycaemic) (NNS effects)) (PP (IN of) (NP (JJ insufficient) (NN insulin) (NN secretion)))) (ADVP-PRP-1 (-NONE- *T*)))))))))) (. .)) )
( (HEADING (NP (NNS Materials) (CC and) (NNS Methods))) )
( (HEADING (NP (NN Islet) (NML (NN isolation) (CC and) (NN culture)) (. .))) )
( (S (NP-SBJ-1 (NP (NNS Islets)) (PP (IN from) (NP (JJ female) (NN NMRI) (NNS mice)))) (VP (VP (VBD were) (VP (VBN isolated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN collagenase) (NN digestion))))) (CC and) (VP (VBN cultured) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NML (NN RPMI) (HYPH -) (CD 1640)) (NNS media) (PRN (-LRB- -LRB-) (NP (NML (CD 5) (NNS mM)) (NN glucose)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (NML (CD 37) (SYM °)) (NNP C)) (CC and) (NP (NML (CD 5) (NN %)) (NN CO2)))) (PP-TMP (IN for) (NP (QP (CD 2) (SYM −) (CD 24)) (NNS h))) (PP-TMP (IN prior) (PP (IN to) (NP (NP (NN secretion)) (CC or) (NP (JJ intracellular) (NN Ca2+) (NNS assays))))))) (. .)) )
( (S (PP-PRP (IN For) (NP (NML (JJ single) (HYPH -) (NN cell)) (NNS studies))) (, ,) (NP-SBJ-1 (NNS islets)) (VP (VBD were) (VP (VP (VBN dispersed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (DT a) (ADJP (NN Ca2+) (HYPH -) (JJ free)) (NN buffer)))) (CC and) (VP (VBN plated) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NML (CD 35) (HYPH -) (NN mm)) (NN plastic) (NNS dishes)))))) (. .)) )
( (S (NP-SBJ-2 (NP (NN Generation)) (PP (IN of) (NP (NP (DT the) (NN Kir6.2Y12X) (NNS mice)) (, ,) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP possess) (NP (DT a) (NN Tyr12STOP) (NN mutation)) (PP-LOC (IN in) (NP (DT the) (NN Kcnj11) (NN gene))) (PP (IN on) (NP (DT a) (NML (NN BALB) (HYPH /) (NN c)) (NN background))))))))) (, ,) (VP (VBZ has) (VP (VBN been) (VP (VBN described) (NP-2 (-NONE- *)) (ADVP (RB previously)) (PRN (-LRB- [) (NP (CD 48)) (-RRB- ]))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VBZ results) (PP (IN in) (NP (JJ nonfunctional) (NN KATP) (NNS channels))) (PP-LOC (IN in) (NP (NML (CC both) (NN α) (CC and) (NN β)) (NNS cells)))) (. .)) )
( (S (NP-SBJ-1 (DT These) (NNS animals)) (VP (VP (VBP are) (RB not) (ADJP-PRD (RB overtly) (JJ diabetic)) (, ,) (S-ADV (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBG exhibiting) (NP (JJ normal) (NN fasting) (NN glucose))))) (, ,) (CC but) (VP (VBP are) (NP-PRD (NN glucose) (JJ intolerant))) (CIT (-LRB- -LRB-) (NNP R.) (NNP Cox) (, ,) (JJ unpublished) (NNS data) (-RRB- -RRB-))) (. .)) )
( (S (PP-PRP (IN For) (NP (DT these) (NNS experiments))) (, ,) (NP-SBJ-1 (ADJP (NP (NN age) (HYPH -) (CC and) (NN weight)) (HYPH -) (VBN matched)) (NML (JJ wild) (HYPH -) (NN type)) (NN C3HB) (NNS mice)) (VP (VBD were) (VP (VBN used) (NP-1 (-NONE- *)) (PP (IN as) (NP (NNS controls))) (SBAR-PRP (IN because) (S (NP-SBJ-2 (DT the) (NN Kir6.2Y12X) (NNS mice)) (VP (VBD were) (VP (RB back) (HYPH -) (VBN crossed) (NP-2 (-NONE- *)) (PP (IN into) (NP (DT this) (NN background))) (PP-TMP (IN over) (NP (JJ several) (NNS generations))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (JJ Human) (NNS islets)) (PP (IN from) (NP (CD four) (JJ healthy) (NNS donors)))) (VP (VBD were) (VP (VBN obtained) (NP-1 (-NONE- *)) (PP (IN from) (NP (DT the) (NNP Oxford) (NNP DRWF) (NML (NML (NNP Human) (NNP Islet)) (NNP Isolation)) (NNP Facility))))) (. .)) )
( (S (NP-SBJ-1 (NNS Experiments)) (VP (VBD were) (VP (VBN performed) (NP-1 (-NONE- *)) (PP-MNR (IN in) (NP (NN duplicate) (CC or) (NN triplicate))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NNS islets)) (PP (IN from) (NP (DT each) (NN donor)))))))) (. .)) )
( (S (S (NP-SBJ-1 (JJ Human) (NNS islets)) (VP (VBD were) (VP (VBN cultured) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN RPMI) (HYPH -) (CD 1640) (PRN (-LRB- -LRB-) (NP (NML (CD 10) (NNS mM)) (NN glucose)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (NML (CD 37) (SYM °)) (NNP C)) (CC and) (NP (NML (CD 5) (NN %)) (NN CO2))))))) (, ,) (CC and) (S (NP-SBJ-2 (NNS experiments)) (VP (VBD were) (VP (VBN performed) (NP-2 (-NONE- *)) (PP-TMP (IN within) (NP (NP (CD 48) (NNS h)) (PP (IN of) (NP (NN isolation)))))))) (. .)) )
( (HEADING (NP (JJ Intracellular) (NN Ca2+) (NNS measurements) (. .))) )
( (S (NP-SBJ-1 (JJ Intact) (NNS islets)) (VP (VBD were) (VP (VBN loaded) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NN fluo) (HYPH -) (CD 4) (HYPH -) (NN AM) (PRN (-LRB- -LRB-) (NP (CD 1) (NN μM)) (-RRB- -RRB-))) (CC and) (NP (NN fura) (NN red) (PRN (-LRB- -LRB-) (NP (CD 5) (NNS μM)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NML (CD 0.5) (NNS mM)) (NN glucose) (NN buffer) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (ADVP (RB below)))) (-RRB- -RRB-))) (PP (IN with) (NP (NML (CD 0.01) (NN %)) (JJ pluronic) (NN acid))))) (PP-TMP (IN for) (NP (CD 30) (NNS min))) (PP (IN at) (NP (CD 37) (NN °C))))) (. .)) )
( (S (NP-SBJ-1 (NNS Islets)) (VP (VBD were) (VP (VBN fixed) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (DT a) (NML (JJ wide) (HYPH -) (NN bore)) (NN holding) (NN pipette))) (PP-LOC (IN within) (NP (DT a) (ADJP (ADJP (RB continuously) (VBN superfused)) (CC and) (ADJP (NN temperature) (HYPH -) (VBN controlled))) (PRN (-LRB- -LRB-) (NP (CD 37) (NN °C)) (-RRB- -RRB-)) (NN bath))) (PP-LOC (IN on) (NP (DT an) (NN Axioskop) (CD 2) (NML (NN FS) (HYPH -) (NN mot)) (NN microscope)) (PRN (-LRB- -LRB-) (NP (NP (NNP Carl) (NNP Zeiss)) (, ,) (NP-ADV (NN http://www.zeiss.com))) (-RRB- -RRB-))))) (. .)) )
( (S (NP-SBJ (DT The) (NN perfusion) (NN buffer)) (VP (VBD contained) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNS mM))) (-RRB- -RRB-)) (: :) (NP (NP (CD 140) (NN NaCl)) (: ;) (NP (CD 3.6) (NN KCl)) (: ;) (NP (CD 2) (NN NaHCO3)) (: ;) (NP (CD 0.5) (NN NaH2PO4)) (: ;) (NP (CD 0.5) (NN MgSO4)) (: ;) (NP (CD 5) (NNS HEPES)) (: ;) (NP (CD 2.5) (NN CaCl2)) (: ;) (NP (NML (CD 0.5) (, ,) (CD 3) (, ,) (CC or) (CD 11)) (NN glucose)) (: ;) (PRN (-LRB- -LRB-) (NP (NP (NN pH) (CD 7.4)) (PP (IN with) (NP (NN NaOH)))) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (ADJP (NN Laser) (VBG scanning)) (JJ confocal) (NN microscopy)) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT an) (NN LSM) (NN 510meta) (NN system) (PRN (-LRB- -LRB-) (NP (NNP Zeiss)) (-RRB- -RRB-))))))) (. .)) )
( (S (S (NP-SBJ (NN Excitation)) (VP (VBD was) (PP-PRD (IN with) (NP (DT a) (NML (CD 488) (HYPH -) (NN nm)) (NN argon) (NN laser))))) (, ,) (CC and) (S (NP-SBJ-1 (VBN emitted) (NN fluorescence)) (VP (VBD was) (VP (VBN collected) (NP-1 (-NONE- *)) (PP-MNR (IN through) (NP (NML (NML (QP (CD 500) (SYM –) (CD 550)) (HYPH -) (NN nm)) (CC and) (NML (QP (CD 650) (SYM –) (CD 710)) (HYPH -) (NN nm))) (NML (NN band) (HYPH -) (NN pass)) (NNS filters))) (PP (IN for) (NP (DT the) (NML (NML (NN fluo) (HYPH -) (CD 4)) (CC and) (NML (NML (NN fura) (NN red)) (-LRB- -LRB-) (NML (NN FuraR)))) (-RRB- -RRB-) (NNS signals))) (, ,) (ADVP (RB respectively))))) (. .)) )
( (S (NP-SBJ-1 (NP (NNS Increases)) (PP (IN in) (NP (JJ intracellular) (NN Ca2+)))) (VP (VBP are) (VP (VBN displayed) (NP-1 (-NONE- *)) (PP (IN as) (NP (JJ upward) (NNS deflections))))) (. .)) )
( (S (NP-SBJ-1 (NNS Images)) (VP (VBD were) (VP (VBN acquired) (NP-1 (-NONE- *)) (PP (IN at) (NP (NML (CD 1.5) (HYPH -) (NN s)) (NNS intervals))))) (. .)) )
( (S (S (NP-SBJ-1 (JJ Individual) (NNS cells)) (VP (VBD were) (VP (VBN selected) (NP-1 (-NONE- *)) (PP (IN as) (NP (NP (NNS regions)) (PP (IN of) (NP (NN interest)))))))) (, ,) (CC and) (S (NP-SBJ-2 (NP (DT the) (JJ average) (NN ratio) (NN intensity) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN RI)) (VP (SYM =) (NP (NP (NP (-LRB- [) (NN Fluo) (SYM +) (CD 1) (-RRB- ])) (SYM /) (NP (-LRB- [) (NN FuraR) (SYM +) (CD 20) (-RRB- ])) (SYM ×) (NP (CD 128))) (SYM +) (NP (CD 1))))) (-RRB- -RRB-))) (PP (IN of) (NP (DT these)))) (VP (VBD were) (VP (VBN analysed) (NP-2 (-NONE- *)) (PP-TMP (IN over) (NP (NN time))) (PP-MNR (IN with) (NP (NN Origin) (NN v7.0220)) (PRN (-LRB- -LRB-) (NP (NP (NNP OriginLab) (NNP Corporation)) (, ,) (NP-ADV (NN http://www.originlab.com))) (-RRB- -RRB-)))))) (. .)) )
( (S (PP-TMP (IN Prior) (PP (IN to) (NP (JJ experimental) (NNS recordings)))) (, ,) (S (S (NP-SBJ-1 (NNS islets)) (VP (VBD were) (VP (VBN perfused) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (CD 10) (NNS min))) (PP (IN with) (NP (DT the) (JJ appropriate) (NN control) (NN solution)))))) (, ,) (CC and) (S (NP-SBJ-2 (NN Ca2+) (NNS responses)) (VP (VBD were) (VP (VBN monitored) (NP-2 (-NONE- *)) (ADVP (RB periodically)) (PP-TMP (IN during) (NP (DT this) (NN time))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB ensure) (SBAR (IN that) (S (NP-SBJ (NP (NNS responses)) (-LRB- -LRB-) (CC or) (NP (NP (NN lack)) (ADVP (RB thereof)))) (-RRB- -RRB-) (VP (VBD were) (ADJP-PRD (JJ stable)) (PP-TMP (IN prior) (PP (IN to) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG beginning) (NP (DT the) (JJ experimental) (NN recording)))))))))))))))) (. .)) )
( (S (NP-SBJ-1 (NN Ca2+) (NNS responses)) (VP (VBD were) (VP (VBN determined) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NN baseline) (NN subtraction)) (CC and) (NP (NP (NN calculation)) (PP (IN of) (NP (DT the) (VBN integrated) (NN response) (PRN (-LRB- -LRB-) (ADVP (FW i.e.)) (, ,) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (DT the) (NN curve)))) (-RRB- -RRB-))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (NP (DT The) (NN slope)) (PP (IN of) (NP (DT this) (NN response)))) (, ,) (VP (VBN reported) (NP (-NONE- *)) (ADVP (RB here)) (PP (IN as) (NP (NP (JJ arbitrary) (NNS units)) (-LRB- -LRB-) (NP (NN AU)))))) (-RRB- -RRB-) (, ,) (VP (VBD was) (VP (VBN calculated) (NP-1 (-NONE- *)) (PP (IN for) (NP (NP (DT the) (JJ final) (NML (NML (CD 60) (NN %)) (PP (SYM –) (NP (CD 90) (NN %))))) (PP (IN of) (NP (DT a) (VBN given) (NN treatment) (NN period))))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB allow) (PP-PRP (IN for) (NP (NP (NN equilibration)) (PP (IN of) (NP (DT the) (NNS responses)))))))))) (. .)) )
( (HEADING (NP (NN Hormone) (NN release) (. .))) )
( (S (NP-SBJ-1 (NML (NN Insulin) (CC and) (NN glucagon)) (NN secretion)) (VP (VBD were) (VP (VBN measured) (NP-1 (-NONE- *)) (SBAR-ADV (IN as) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN described) (NP-2 (-NONE- *)) (ADVP (RB elsewhere))))) (PRN (-LRB- [) (NP (CD 45)) (-RRB- ])))) (. .)) )
( (S (ADVP (RB Briefly)) (, ,) (NP-SBJ-1 (NP (NNS batches)) (PP (IN of) (NP (CD ten) (ADJP (RB freshly) (VBN isolated)) (NNS islets)))) (VP (VBD were) (VP (VBN pre-incubated) (NP-1 (-NONE- *)) (PP (IN in) (NP (NP (NP (CD 1) (NN ml)) (PP (IN of) (NP (NP (NML (NNP Krebs) (HYPH –) (NNP Ringer)) (NN buffer)) (-LRB- -LRB-) (NP (NN KRB))))) (-RRB- -RRB-) (VP (VBN supplemented) (NP (-NONE- *)) (PP (IN with) (NP (NML (CD 1) (NN mM)) (NN glucose)))))) (PP-TMP (IN for) (NP (NP (CD 30) (NNS min) (PRN (-LRB- -LRB-) (NP (NN rodent)) (-RRB- -RRB-))) (CC or) (NP (CD 1) (NN h) (PRN (-LRB- -LRB-) (NP (JJ human)) (-RRB- -RRB-))))) (S-ADV (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN followed) (NP-2 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NML (CD 1) (HYPH -) (NN h)) (NN incubation)) (PP-LOC (IN in) (NP (NP (NP (CD 1) (NN ml)) (PP (IN of) (NP (NN test) (NN KRB) (NN medium)))) (VP (VBN supplemented) (NP (-NONE- *)) (SBAR-ADV (IN as) (S (NP-SBJ-4 (-NONE- *PRO*)) (VP (VBN indicated) (NP-4 (-NONE- *)))))))))))))) (. .)) )
( (S (PP-PRP (IN For) (NP (NP (NNS experiments)) (SBAR (WHPP-3 (IN in) (WHNP (WDT which))) (S (S (S (NP-SBJ-1 (NN Zn2+)) (VP (VBD was) (VP (VBN chelated) (NP-1 (-NONE- *))))) (CC or) (S (NP-SBJ-2 (NN GABAA) (NNS receptors)) (VP (VBD were) (VP (VBN antagonised) (NP-2 (-NONE- *)))))) (PP-3 (-NONE- *T*)) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 1)) (-RRB- -RRB-)))))) (, ,) (NP-SBJ (DT the) (NML (NML (NN Ca2+) (HYPH -) (NN EDTA)) (CC and) (NML (NN SR) (HYPH -) (CD 95531)))) (, ,) (ADVP (RB respectively)) (, ,) (VP (VBD were) (ADJP-PRD (JJ present)) (PP (IN in) (NP (CC both) (DT the) (UCP (JJ pre-incubation) (CC and) (NN test)) (NNS solutions)))) (. .)) )
( (S (SBAR-TMP (WHADVP-2 (WRB When)) (S (NP-SBJ-1 (JJ extracellular) (NN KCl)) (VP (VBD was) (VP (VBN increased) (NP-1 (-NONE- *)) (ADVP-TMP-2 (-NONE- *T*)))))) (, ,) (NP-SBJ-3 (NN NaCl)) (VP (VBD was) (ADVP (RB correspondingly)) (VP (VBN reduced) (NP-3 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB maintain) (NP (NN iso) (HYPH -) (NN osmolarity))))))) (. .)) )
( (HEADING (NP (NP (NML (JJ Single) (HYPH -) (NN cell)) (NN capacitance)) (CC and) (NP (NML (NN ion) (NN current)) (NNS measurements)) (. .))) )
( (S (NP-SBJ-1 (NP (NML (JJ Whole) (HYPH -) (NN cell)) (NNS currents)) (CC and) (NP (NN exocytosis))) (VP (VBD were) (VP (VBN recorded) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT an) (NML (NN EPC) (HYPH -) (CD 9)) (NML (NN patch) (HYPH -) (NN clamp)) (NN amplifier) (PRN (-LRB- -LRB-) (NP (NP (NNP HEKA) (NNP Electronics)) (, ,) (NP-ADV (NN http://www.heka.com))) (-RRB- -RRB-))) (CC and) (NP (NNP Pulse) (NN software) (PRN (-LRB- -LRB-) (NP (NN version) (CD 8.50)) (-RRB- -RRB-)))))))) (. .)) )
( (S (NP-SBJ-1 (JJ Single) (NN α) (NNS cells)) (VP (VBD were) (VP (VBN identified) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (PRP$ their) (NML (NML (JJ small) (NN size)) (CC and) (NML (NML (NN Na+) (JJ current)) (NN inactivation) (NNS properties))))) (PRN (-LRB- [) (NP (CD 58)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN method)) (VP (VBD was) (VP (VBN validated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG combining) (NP (DT the) (JJ electrophysiological) (NNS recordings)) (PP (IN with) (NP (NP (JJ subsequent) (NN immunostaining)) (PP (IN for) (NP (NN glucagon) (CC and) (NN insulin)))))))))) (. .)) )
( (S (NP-SBJ (DT The) (JJ extracellular) (NN medium)) (VP (VBN contained) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNS mM))) (-RRB- -RRB-)) (: :) (NP (NP (CD 118) (NN NaCl)) (: ;) (NP (CD 20) (NML (NML (NN TEA) (HYPH -) (NN Cl)) (-LRB- -LRB-) (NML (NN tetraethylammonium) (NN chloride)))) (-RRB- -RRB-) (: ;) (NP (CD 5.6) (NN KCl)) (: ;) (NP (CD 2.6) (NN CaCl2)) (: ;) (NP (CD 1.2) (NN MgCl2)) (: ;) (NP (CD 5) (NN HEPES) (PRN (-LRB- -LRB-) (NP (NP (NN pH) (CD 7.4)) (PP (IN with) (NP (NN NaOH)))) (-RRB- -RRB-))) (: ;) (CC and) (NP (CD 5) (NN glucose)))) (. .)) )
( (S (PP (IN Except) (PP (IN for) (NP (NP (NN Figure) (NML (NN 8B) (CC and) (NN 8C))) (, ,) (SBAR (WHPP-2 (IN in) (WHNP (WDT which))) (S (NP-SBJ-1 (DT the) (JJ standard) (NML (JJ whole) (HYPH -) (NN cell)) (NN configuration)) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (PP-2 (-NONE- *T*))))))))) (, ,) (S (S (NP-SBJ-3 (DT the) (JJ electrophysiological) (NNS measurements)) (VP (VBD were) (VP (VBN conducted) (NP-3 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT the) (VBN perforated) (NN patch) (NN technique))))))) (, ,) (CC and) (S (NP-SBJ (DT the) (NN pipette) (NN solution)) (VP (VBD contained) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNS mM))) (-RRB- -RRB-)) (: :) (NP (NP (CD 76) (NN Cs2SO4)) (: ;) (NP (CD 10) (NN NaCl)) (: ;) (NP (CD 10) (NN KCl)) (: ;) (NP (CD 1) (NN MgCl2)) (: ;) (CC and) (NP (CD 5) (NN HEPES) (PRN (-LRB- -LRB-) (NP (NP (NN pH) (CD 7.35)) (PP (IN with) (NP (NN CsOH)))) (-RRB- -RRB-))))))) (. .)) )
( (S (NP-SBJ-1 (NN Exocytosis)) (VP (VBD was) (VP (VBN monitored) (NP-1 (-NONE- *)) (PP (IN as) (NP (NP (NNS changes)) (PP (IN in) (NP (NML (NN α) (HYPH -) (NN cell)) (NN capacitance))))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT the) (ADJP (NN software) (HYPH -) (VBN based)) (ADJP (VB lock) (HYPH -) (RP in)) (NN function)) (PP (IN of) (NP (DT the) (NN Pulse) (NN software)))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (JJ standard) (NML (JJ whole) (HYPH -) (NN cell)) (NNS measurements) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 8B) (CC and) (NN 8C))) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN conducted) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NP (DT a) (NN pipette) (NN solution)) (-LRB- -LRB-) (VP (VBG dialyzing) (NP (DT the) (NN cell) (NN interior))) (-RRB- -RRB-)) (VP (VBN consisted) (NP (-NONE- *)) (PP (IN of) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNS mM))) (-RRB- -RRB-)) (NP (NP (CD 125) (NN CsOH)) (: ;) (NP (CD 125) (NN glutamate)) (: ;) (NP (CD 10) (NN CsCl)) (: ;) (NP (CD 10) (NN NaCl)) (: ;) (NP (CD 1) (NN MgCl2)) (: ;) (NP (CD 5) (NN HEPES) (PRN (-LRB- -LRB-) (NP (NP (NN pH) (CD 7.15)) (PP (IN with) (NP (NN KOH)))) (-RRB- -RRB-))) (: ;) (NP (CD 3) (NNS Mg) (HYPH -) (NN ATP)) (: ;) (CC and) (NP (NML (NML (CD 25) (NNS μmol)) (PP (SYM /) (NP (NN l)))) (NN EGTA) (PRN (-LRB- -LRB-) (NP (VBN measured) (VBG resting) (JJ free) (NN Ca2+)) (, ,) (NP (NP (QP (SYM ∼) (CD 0.2)) (NNS μmol)) (PP (SYM /) (NP (NN l)))) (-RRB- -RRB-))))))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Pulses)) (VP (VBD were) (VP (VBN applied) (NP-1 (-NONE- *)) (PP (IN at) (NP (NP (JJ low) (NN frequency)) (-LRB- -LRB-) (ADJP (SYM <) (NP (CD 0.05) (NN Hz))) (-RRB- -RRB-))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB allow) (S (NP-SBJ (DT the) (JJ exocytotic) (NN capacity)) (VP (TO to) (VP (VB recover) (ADVP (RB fully)) (PP-TMP (IN between) (NP (DT the) (NNS pulses))))))))))) (. .)) )
( (HEADING (NP (JJ Statistical) (NN analysis) (. .))) )
( (S (NP-SBJ-1 (NNS Data)) (VP (VBP are) (VP (VBN presented) (NP-1 (-NONE- *)) (PP (IN as) (NP (NP (NNS means)) (CC and) (NP (JJ standard) (NNS errors)))))) (. .)) )
( (S (NP-SBJ-1 (NN Significance)) (VP (VBD was) (VP (VBN examined) (NP-1 (-NONE- *)) (PP-MNR (PP (IN by) (CC either) (NP (DT the) (JJ unpaired) (NML (NN t) (HYPH -) (NN test)))) (CC or) (PP (IN by) (NP (NP (NP (NML (JJ multiple) (HYPH -) (NNS comparisons)) (NN analysis)) (PP (IN of) (NP (NN variance))) (PRN (-LRB- -LRB-) (NP (NN ANOVA)) (-RRB- -RRB-))) (CC and) (NP (RB post-test))))) (, ,) (SBAR-ADV (IN as) (FRAG (ADJP (JJ appropriate)))))) (. .)) )
( (HEADING (NP (NNS Acknowledgements))) )
( (S (NP-SBJ-1 (NNP PEM)) (VP (VP (VBD was) (VP (VBN supported) (NP-1 (-NONE- *)) (ADVP (RB initially)) (NP-ADV (NP (NP (NP (DT the) (JJ European) (NN Foundation)) (PP (IN for) (NP (NP (DT the) (NN Study)) (PP (IN of) (NP (NN Diabetes)))))) (-LRB- -LRB-) (NP (NN EFSD))) (-RRB- -RRB-) (HYPH /) (NP (NP (NNP AstraZeneca) (NNP Fellowship)) (PP (IN in) (NP (NNP Islet) (NNP Biology))))))) (CC and) (VP (VBZ is) (ADVP (RB currently)) (NP-PRD (NP (DT an) (NML (NML (NNP Alberta) (NNP Heritage) (NNP Foundation)) (PP (IN for) (NP (NNP Medical) (NNP Research)))) (NNP Scholar)) (, ,) (NP (NNP Canadian) (NML (NNP Diabetes) (NNP Association)) (NNP Scholar)) (, ,) (CC and) (NP (NP (DT the) (NNP Canada) (NNP Research) (NNP Chair)) (PP (IN in) (NP (NNP Islet) (NNP Biology))))))) (. .)) )
( (S (NP-SBJ (NNP PR)) (VP (VBZ is) (NP-PRD (DT a) (NNP Wolfson) (NML (NNP Royal) (NNP Society)) (NML (NNP Merit) (NNP Award)) (NNP Research) (NNP Fellow))) (. .)) )
( (HEADING (NP (NNS Abbreviations))) )
( (NP (NP (-LRB- [) (NN Ca2+) (-RRB- ]) (NN i)) (: -) (NP (JJ intracellular) (NN Ca2+))) )
( (NP (NP (NN FuraR)) (: -) (NP (NN fura) (JJ red))) )
( (NP (NP (NN GABA)) (: -) (NP (ADJP (NN γ) (HYPH -) (JJ aminobutyric)) (NN acid))) )
( (NP (NP (NP (NN KATP)) (: -) (NP (ADJP (NN ATP) (HYPH -) (JJ dependent)) (NN K+))) (, ,) (NP (NN TTX) (, ,) (NN tetrodotoxin))) )
( (NP (NP (NN VDCC)) (: -) (NP (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN Ca2+) (NN channel))) )
( (HEADING (NP (NNS Figures) (CC and) (NNS Tables))) )
( (HEADING (NP (NN Figure) (CD 1))) )
( (HEADING (S (NP-SBJ (NN Glucose)) (VP (VBZ Suppresses) (NP (NN Glucagon) (NN Release)) (ADVP (RB Independently) (PP (IN of) (NP (NP (NN Paracrine) (NNS Signals)) (VP (VBN Mediated) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NN Zn2+) (CC or) (NN GABA)))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ-1 (NP (NN Glucagon) (NN release)) (PP-LOC (IN from) (NP (VBN isolated) (NN mouse) (NNS islets)))) (VP (VBD was) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP-EXT (IN by) (NP (CD 60) (NN %))) (PP (IN at) (NP (NML (CD 7) (NNS mM)) (NN glucose))) (PP (VBN compared) (PP (IN with) (NP (CD 1) (NN mM)))) (PRN (-LRB- -LRB-) (NP (VBN filled) (NNS bars)) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (S (NP-SBJ (NN Glucose)) (VP (VBD retained) (NP (NP (PRP$ its) (JJ suppressive) (NN effect)) (PP (IN on) (NP (NN glucagon) (NN release)))) (PP (IN under) (NP (NP (NNS conditions)) (PP (IN of) (NP (NP (NN Zn2+) (NN chelation) (PRN (-LRB- -LRB-) (NP (NN Ca2+) (HYPH -) (NN EDTA)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS bars)) (-RRB- -RRB-))) (CC and) (NP (NP (NN antagonism)) (PP (IN of) (NP (NN GABAA) (NNS receptors))) (PRN (-LRB- -LRB-) (NP (NN SR) (HYPH -) (CD 95531)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (VBN shaded) (NNS bars)) (-RRB- -RRB-)))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (NN Antagonism)) (PP (IN of) (NP (NN GABAA) (NNS receptors)))) (VP (VBD increased) (NP (ADJP (CC both) (ADJP (JJ basal)) (CC and) (ADJP (NN glucose) (HYPH -) (VBN suppressed))) (NN glucagon) (NN secretion)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (NP (NP (NP (DT a) (JJ paracrine) (NN role)) (PP (IN for) (NP (NN GABA)))) (ADJP (JJ independent) (PP (IN of) (NP (DT the) (NN glucose) (NN effect)))))))) (. .))) )
( (CAPTION (UCP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (PP (IN As) (PP (IN in) (-LRB- -LRB-) (NP (NN A)))) (-RRB- -RRB-) (, ,) (CC but) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NN rat) (NNS islets)))) (. .))) )
( (CAPTION (S (S (S-FRM (SYM *) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (SYM **) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (SYM ***) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (UCP-ADV (PP (VBN compared) (PP (IN with) (NP (NML (CD 1) (NN mM)) (NN glucose)))) (, ,) (CC or) (SBAR (IN as) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN indicated) (NP-2 (-NONE- *)))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 2))) )
( (HEADING (S (NP-SBJ-1 (NP (NN Glucagon) (NN Release)) (PP (IN from) (NP (NML (VBN Isolated) (CC and) (JJ Intact)) (NN Mouse) (NNS Islets)))) (VP (VBZ Is) (VP (VBN Regulated) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (DT a) (NN KATP) (ADJP (NN Channel) (HYPH -) (JJ Dependent)) (NN Pathway))))))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (NML (NML (NN Glucagon) (PRN (-LRB- -LRB-) (NP (VBN filled) (NNS circles)) (-RRB- -RRB-))) (CC and) (NML (NN insulin) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS circles)) (-RRB- -RRB-)))) (NN secretion)) (VP (VBN measured) (NP (-NONE- *)) (PP (IN from) (NP (NN mouse) (NNS islets))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NML (CD 8.3) (NNS mM)) (NN glucose))))) (PP (IN at) (NP (NP (VBG increasing) (NNS concentrations)) (PP (IN of) (NP (NN diazoxide)))))) (. .))) )
( (CAPTION (UCP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (PP (IN As) (PP (IN in) (-LRB- -LRB-) (NP (NN A)))) (-RRB- -RRB-) (, ,) (CC but) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NN rat) (NNS islets)))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (DT The) (NN glucagon) (NNS responses)) (PP (IN to) (NP (NP (NML (CD 1) (NN mM)) (NN glucose) (PRN (-LRB- -LRB-) (NP (VBN filled) (NN square)) (-RRB- -RRB-))) (CC and) (NP (NML (CD 100) (NNS μM)) (NN tolbutamide) (PRN (-LRB- -LRB-) (NP (VBN filled) (NN triangle)) (-RRB- -RRB-)))))) (VP (VBP are) (VP (VBN indicated) (NP-1 (-NONE- *)))) (. .))) )
( (CAPTION (UCP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (PP (IN As) (PP (IN in) (-LRB- -LRB-) (NP (NN A)))) (-RRB- -RRB-) (, ,) (CC but) (UCP (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NML (CD 1) (NN mM)) (NN glucose))))) (CC and) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADVP (RB only)) (VP (VBG measuring) (NP (NN glucagon) (NN secretion))))) (. .))) )
( (CAPTION (UCP (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (PP (IN As) (PP (IN in) (-LRB- -LRB-) (NP (NN A)))) (-RRB- -RRB-) (, ,) (CC but) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG examining) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN tolbutamide)))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN glucose))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (NN Glucagon) (NN secretion)) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NML (CD 20) (NNS mM)) (NN glucose)))))) (VP (VBZ is) (VP (VBN indicated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (DT the) (VBN filled) (NN square))))) (. .))) )
( (CAPTION (S (S (S-FRM (SYM *) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (SYM **) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (SYM ***) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD zero) (NN diazoxide) (PRN (-LRB- -LRB-) (NP (NP (NN A)) (PP (SYM –) (NP (NN C)))) (-RRB- -RRB-))) (CC or) (NP (CD zero) (NN tolbutamide) (PRN (-LRB- -LRB-) (NP (NN D)) (-RRB- -RRB-)))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 3))) )
( (HEADING (S (S (NP-SBJ (NML (NN Tolbutamide) (CC and) (NN Glucose)) (NNS Effects)) (VP (VBP Are) (ADJP-PRD (JJ Non-Additive)))) (CC and) (S (NP-SBJ-1 (NN Glucagon) (NN Response)) (VP (VBZ Is) (VP (VBN Altered) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NN Kir6.2Y12X) (NNS Islets)) (SBAR (WHNP-2 (WDT That)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP Express) (NP (DT a) (VBN Truncated) (NN Kir6.2) (NN Subunit)))))))))))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (NN Glucagon) (NN release)) (PP (IN from) (NP (VBN isolated) (NN mouse) (NNS islets))) (PP (IN at) (NP (NML (NML (NML (CD 1) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS bars)) (-RRB- -RRB-))) (CC and) (NML (CD 20))) (NNS mM)) (NN glucose) (PRN (-LRB- -LRB-) (NP (VBN filled) (NNS bars)) (-RRB- -RRB-)))) (PP (IN under) (NP (NP (NN control) (NNS conditions)) (CC and) (NP (NP (NN presence)) (PP (IN of) (NP (NML (CD 0.5) (NNS mM)) (NN tolbutamide)))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (DT A) (NN glucose) (NN dose) (HYPH -) (NN response)) (PP (IN of) (NP (NN glucagon) (NN release))) (PP (IN from) (NP (NP (NN control) (NN C3HB) (NNS islets) (PRN (-LRB- -LRB-) (NP (VBN filled) (NNS circles)) (-RRB- -RRB-))) (CC and) (NP (NN Kir6.2Y12X) (NNS islets) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS circles)) (-RRB- -RRB-))))) (. .))) )
( (CAPTION (UCP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (PP (IN As) (PP (IN in) (-LRB- -LRB-) (NP (NN B)))) (-RRB- -RRB-) (, ,) (CC but) (S (NP-SBJ-1 (NN insulin)) (VP (VBD was) (VP (VBN measured) (NP-1 (-NONE- *))))) (. .))) )
( (CAPTION (S (S (S-FRM (SYM *) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (SYM **) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (SYM ***) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NN control)))) (. .))) )
( (HEADING (NP (NN Figure) (CD 4))) )
( (HEADING (S (NP-SBJ-1 (NP (DT The) (JJ Intracellular) (NN Ca2+) (NN Response)) (PP (IN of) (NP (JJ Single) (NN α) (NNS Cells))) (PP-LOC (IN within) (NP (JJ Intact) (NNS Islets)))) (VP (MD Can) (VP (VB Be) (VP (VBN Re-Activated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (JJ Low) (NNS Concentrations)) (PP (IN of) (NP (NN Diazoxide)))))))))) )
( (CAPTION (FRAG (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (JJ Representative) (JJ intracellular) (NN Ca2+) (NNS responses)) (PP (IN from) (NP (NML (NN α) (CC and) (NN β)) (NNS cells))) (PP-LOC (IN within) (NP (NP (DT an) (JJ intact) (NN mouse) (NN islet)) (VP (VBN exposed) (NP (-NONE- *)) (PP (IN to) (NP (NP (NP (NML (CD 0.5) (NNS mM)) (NN glucose)) (, ,) (NP (NML (CD 11) (NNS mM)) (NN glucose)) (, ,) (CC and) (NP (NML (CD 11) (NNS mM)) (NN glucose))) (CC plus) (NP (NML (CD 2) (NNS μM)) (NN diazoxide) (PRN (-LRB- -LRB-) (NP (NN diaz)) (-RRB- -RRB-))))) (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN indicated) (NP-1 (-NONE- *)) (PP (IN above) (NP (DT the) (NNS traces))))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP-SBJ-1 (NP (DT The) (NN Ca2+) (NN response)) (PP (IN of) (NP (NN α) (NNS cells)))) (VP (VP (VBD was) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NML (CD 11) (NNS mM)) (NN glucose))))) (, ,) (CC and) (VP (MD could) (VP (VB be) (VP (VBN reactivated) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (JJ low) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (NML (NML (NN KATP) (NN channel)) (NN agonist))) (NP (NN diazoxide)))))))))) (. .))) )
( (CAPTION (S-FRM (SYM ***) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (, ,) (UCP-ADV (PP (VBN compared) (PP (IN with) (NP (DT the) (NML (JJ low) (HYPH -) (NN glucose)) (NN condition)))) (, ,) (CC or) (SBAR (IN as) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN indicated) (NP-2 (-NONE- *))))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 5))) )
( (HEADING (S (NP-SBJ-1 (NP (NN Glucagon) (NN Release)) (PP (IN from) (NP (ADJP (VBN Isolated) (CC and) (JJ Intact)) (JJ Human) (NNS Islets)))) (VP (VBZ Is) (VP (VBN Regulated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (DT a) (ADJP (NP (NN KATP) (NN Channel)) (HYPH -) (JJ Dependent)) (NN Pathway))))))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ-1 (NML (NML (NN Glucagon) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS bars)) (-RRB- -RRB-))) (CC and) (NML (NN insulin) (PRN (-LRB- -LRB-) (NP (VBN filled) (NNS bars)) (-RRB- -RRB-)))) (NN release)) (VP (VBD was) (VP (VBN measured) (NP-1 (-NONE- *)) (PP (IN from) (NP (VBN isolated) (JJ human) (NNS islets))) (PP (PP (IN under) (NP (NN control) (NNS conditions))) (CC and) (PP (VBG following) (NP (NP (NN addition)) (PP (IN of) (NP (NP (NML (CD 10) (NNS mM)) (NN glucose)) (CC or) (NP (NML (CD 200) (NNS μM)) (NN tolbutamide))))))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (NML (NML (NN Glucagon) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS bars)) (-RRB- -RRB-))) (CC and) (NML (NN insulin))) (NN secretion) (PRN (-LRB- -LRB-) (NP (VBN filled) (NNS bars)) (-RRB- -RRB-))) (VP (VBN measured) (NP (-NONE- *)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NML (CD 10) (NNS mM)) (NN glucose)) (CC and) (NP (NP (VBG increasing) (NNS concentrations)) (PP (IN of) (NP (NN diazoxide) (PRN (-LRB- -LRB-) (NP (QP (CD 0) (SYM –) (CD 200)) (NNS μM)) (-RRB- -RRB-)))))))))) (. .))) )
( (CAPTION (S (S (S-FRM (SYM *) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (SYM **) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (SYM ***) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NNS controls)))) (, ,) (SBAR-ADV (IN unless) (S (NP-SBJ-2 (-NONE- *PRO*)) (ADVP (RB otherwise)) (VP (VBN indicated) (NP-2 (-NONE- *))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 6))) )
( (HEADING (S (NP-SBJ-1 (NP (JJ Intracellular) (NN Ca2+) (NNS Responses)) (PP (IN of) (NP (NN α) (NNS Cells))) (PP-LOC (IN within) (NP (JJ Intact) (JJ Human) (NNS Islets)))) (VP (VBP Are) (VP (VBN Regulated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (DT a) (ADJP (NP (NN KATP) (NN Channel)) (HYPH -) (JJ Dependent)) (NN Mechanism))))))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (NN Ca2+) (NNS responses)) (VP (VBN measured) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NP (CD two) (JJ human) (NN α) (NNS cells)) (PP-LOC (IN within) (NP (DT the) (JJ same) (NN islet))))) (PP (IN at) (NP (NML (NML (CD 0.5) (NNS mM)) (CC and) (NML (CD 11) (NNS mM))) (NN glucose) (PRN (-LRB- -LRB-) (NP (NN glu)) (-RRB- -RRB-)))) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NML (CD 2) (NNS μM)) (NN diazoxide) (PRN (-LRB- -LRB-) (NP (NN diaz)) (-RRB- -RRB-))))))) (. .))) )
( (CAPTION (FRAG (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (NP (NN Summary)) (PP (IN of) (NP (DT the) (NN Ca2+) (NNS responses)))) (PP (PP (IN at) (NP (NML (CD 0.5) (NNS mM)) (NN glucose))) (, ,) (PP (IN at) (NP (NML (CD 11) (NNS mM)) (NN glucose))) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN glucose) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS mM)) (-RRB- -RRB-))) (CC and) (NP (NN diazoxide) (PRN (-LRB- -LRB-) (NP (CD 2) (NNS μM)) (-RRB- -RRB-))))))) (, ,) (CC and) (PP (PP-TMP (IN following) (NP (NP (DT the) (NN removal)) (PP (IN of) (NP (NN diazoxide))))) (, ,) (CC but) (PP (IN in) (NP (NP (DT the) (VBN continued) (NN presence)) (PP (IN of) (NP (NML (CD 11) (NNS mM)) (NN glucose))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP-SBJ-1 (NP (DT The) (NN re-activation)) (PP (IN of) (NP (JJ human) (NML (NN α) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses))) (PP (IN by) (NP (NML (CD 2) (NNS μM)) (NN diazoxide)))) (VP (VBD was) (VP (VBN reversed) (NP-1 (-NONE- *)) (PP-TMP (IN upon) (NP (NP (NN application)) (PP (IN of) (NP (NP (DT the) (NML (NML (NN KATP) (NN channel)) (NN antagonist))) (NP (NN tolbutamide)) (PRN (-LRB- -LRB-) (NP (CD 100) (NNS μM)) (-RRB- -RRB-)))))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (VBG increasing) (NNS concentrations)) (PP (IN of) (NP (NN diazoxide))))) (PP (IN on) (NP (NP (DT the) (NN Ca2+) (NN response)) (PP (IN of) (NP (DT a) (JJ human) (NML (NML (NN α) (NN cell)) (CC and) (NML (NN β) (NN cell))))))) (PP-LOC (IN within) (NP (NP (DT the) (JJ same) (NN islet)) (VP (VBN exposed) (NP (-NONE- *)) (PP (IN to) (NP (NML (CD 11) (NNS mM)) (NN glucose)))))) (. .))) )
( (CAPTION (S (PP-TMP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN experiment))))) (, ,) (S (S (NP-SBJ-1=4 (NN diazoxide)) (VP (VBD was) (VP=3 (VBN withdrawn) (NP-1 (-NONE- *))))) (CC and) (S (NP-SBJ-2=4 (NN glucose)) (VP=3 (VBN lowered) (NP-2 (-NONE- *)) (PP (IN to) (NP (CD 0.5) (NNS mM)))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS E) (-RRB- -RRB-)) (NP (NML (NN Dose) (HYPH -) (JJ response)) (NN curve)) (PP (IN for) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN diazoxide))) (PP (IN on) (NP (NML (NN α) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses))))) (. .))) )
( (CAPTION (S (NP-SBJ (DT The) (JJ grey) (JJ horizontal) (NN line)) (VP (VBZ indicates) (NP (NP (DT the) (NN response)) (PP (IN with) (NP (NP (NML (CD 11) (NNS mM)) (NN glucose)) (ADVP (RB alone)))))) (. .))) )
( (CAPTION (S (S (S-FRM (SYM *) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (SYM **) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (SYM ***) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NNS controls)))) (, ,) (SBAR-ADV (IN unless) (S (NP-SBJ-2 (-NONE- *PRO*)) (ADVP (RB otherwise)) (VP (VBN indicated) (NP-2 (-NONE- *))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 7))) )
( (HEADING (S (NP-SBJ (NP (NN Glucagon) (NN Secretion)) (CC and) (NP (NML (NN α) (HYPH -) (NN Cell)) (NN Ca2+) (NNS Responses))) (VP (VBP Are) (ADJP-PRD (JJ Dependent) (PP (IN upon) (NP (NP (DT the) (NN Activity)) (PP (IN of) (NP (ADJP (NN Voltage) (HYPH -) (JJ Dependent)) (NN Na+) (NNS Channels))))))))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ (NP (NN Glucagon) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS bars)) (-RRB- -RRB-))) (CC and) (NP (NN insulin) (PRN (-LRB- -LRB-) (NP (VBN filled) (NNS bars)) (-RRB- -RRB-)))) (VP (VBP release) (PP (IN from) (NP (VBN isolated) (NN mouse) (NNS islets))) (PP (IN at) (NP (NML (NML (CD 1) (NN mM)) (CC and) (NML (CD 20) (NNS mM))) (NN glucose))) (, ,) (PP (PP (IN under) (NP (NN control) (NNS conditions))) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT the) (NML (NN Na+) (NN channel)) (NN antagonist)) (NP (NN TTX)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (NNS μg)) (PP (SYM /) (NP (NN ml)))) (-RRB- -RRB-)))))))) (. .))) )
( (CAPTION (FRAG (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (JJ Intracellular) (NN Ca2+) (NN response)) (PP (IN of) (NP (JJ single) (NN α) (NNS cells))) (PP (IN to) (NP (NML (CD 0.5) (NNS mM)) (NN glucose))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NN TTX) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (NNS μg)) (PP (SYM /) (NP (NN ml)))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN included) (NP-1 (-NONE- *)) (PP (IN in) (NP (DT the) (NN perfusion) (NN medium))) (PP-TMP (IN during) (NP (DT the) (VBN indicated) (NN period))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN TTX) (CC and) (NN glucose))) (PP (IN on) (NP (NML (NN α) (HYPH -) (NN cell)) (NN Ca2+) (NNS responses))) (. .))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Note) (SBAR (SBAR (IN that) (S (NP-SBJ (NN TTX)) (VP (VBZ inhibits) (NP (NN Ca2+) (NNS responses)) (ADVP (ADVP (RB as) (RB effectively)) (PP (IN as) (NP (NN glucose))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (DT the) (NN action)) (VP (VBZ is) (ADJP-PRD (ADVP (ADVP (RB at) (RB least)) (RB partially)) (JJ reversible))))))) (. .))) )
( (CAPTION (S (S (S-FRM (SYM *) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (SYM **) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (SYM ***) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NNS controls)))) (, ,) (SBAR-ADV (IN unless) (S (NP-SBJ-2 (-NONE- *PRO*)) (ADVP (RB otherwise)) (VP (VBN indicated) (NP-2 (-NONE- *))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 8))) )
( (HEADING (S (NP-SBJ-1 (NN Glucagon) (NN Secretion)) (VP (VBZ Is) (VP (VBN Regulated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NML (NN N) (HYPH -) (NN Type)) (NN Ca2+) (NNS Channels))))))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (NN Glucagon) (NN release)) (VP (VBN measured) (NP (-NONE- *)) (PP (IN at) (NP (NML (NML (NML (CD 1) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS bars)) (-RRB- -RRB-))) (CC and) (NML (CD 20))) (NNS mM)) (NN glucose) (PRN (-LRB- -LRB-) (NP (VBN filled) (NNS bars)) (-RRB- -RRB-)))) (PP (PP (IN under) (NP (NN control) (NNS conditions))) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NML (CD 100) (NNS nM)) (NN ω) (HYPH -) (NN conotoxin) (PRN (-LRB- -LRB-) (ADJP (JJ middle)) (-RRB- -RRB-))) (CC or) (NP (NML (CD 20) (NNS μM)) (NN nifedipine) (PRN (-LRB- -LRB-) (ADJP (JJ right)) (-RRB- -RRB-))))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP-SBJ-1 (NN Exocytosis)) (VP (VBD was) (VP (VBN elicited) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NML (CD 500) (HYPH -) (NNS ms)) (NNS depolarisations)) (PP (PP (IN from) (NP (QP (SYM −) (CD 70)) (NML-2 (-NONE- *RNR*)))) (PP (IN to) (NP (CD 0) (NML-2 (-NONE- *RNR*))))) (NML-2 (NN mV)))) (PP (PP (IN under) (NP (NP (NN control) (NNS conditions)) (-LRB- -LRB-) (NP (NN Ctrl)))) (-RRB- -RRB-) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (CC either) (NP (NN nifedipine) (PRN (-LRB- -LRB-) (NP (CD 50) (NNS μM)) (: ;) (NP (NN nif)) (-RRB- -RRB-))) (CC or) (NP (NN ω) (HYPH -) (NN conotoxin) (PRN (-LRB- -LRB-) (NP (CD 1) (NN μM)) (: ;) (NP (SYM ω) (HYPH -) (NN con)) (-RRB- -RRB-)))))))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP (NN Summary)) (PP (IN of) (NP (DT the) (JJ exocytotic) (NN response))) (PP (PP (IN under) (NP (NN control) (NNS conditions))) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN nifedipine)) (CC and) (NP (NN ω) (HYPH -) (NN conotoxin))))))) (. .))) )
( (CAPTION (S (S (S-FRM (SYM *) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (SYM **) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (NML (CD 1) (NN mM)) (NN glucose)) (CC and) (NP (DT the) (NN control) (NN capacitance) (NN response))))) (, ,) (SBAR-ADV (IN unless) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN indicated) (NP-2 (-NONE- *)) (ADVP (RB otherwise))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 9))) )
( (HEADING (NP (NP (ADJP (NN Voltage) (HYPH -) (JJ Dependent)) (NN Inactivation)) (PP (IN of) (NP (NP (NML (NN α) (HYPH -) (NN Cell)) (NML (NN N) (HYPH -) (NN Type)) (NN Ca2+) (NNS Currents)) (CC and) (NP (NN Exocytosis)))))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ-1 (NML (NN N) (HYPH -) (NN type)) (NN Ca2+) (NNS currents)) (VP (VBD were) (VP (VBN evaluated) (NP-1 (-NONE- *)) (PP-TMP (IN during) (NP (NP (NN blockade)) (PP (IN of) (NP (DT the) (NML (NN L) (HYPH -) (NN type)) (NNS channels))))) (PP-MNR (IN with) (NP (NN isradipine) (PRN (-LRB- -LRB-) (NP (CD 2) (NNS μM)) (-RRB- -RRB-)))))) (. .))) )
( (S (NP-SBJ (NP (DT The) (NML (NML (NN N) (HYPH -) (NN type)) (NN channel)) (NN antagonist)) (NP (NN ω) (HYPH -) (NN conotoxin)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN μM)) (: ;) (NP (JJ red) (NNS traces)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NP (DT the) (NN Ca2+) (NN current)) (VP (VBN elicited) (NP (-NONE- *)) (PP-MNR (IN by) (NP (DT a) (NN step) (NN depolarisation))))) (PP (PP (IN from) (NP (QP (SYM −) (CD 70)) (NML-1 (-NONE- *RNR*)))) (PP (IN to) (NP (CD 0) (NML-1 (-NONE- *RNR*)))) (NML-1 (NNS mV))) (PRN (-LRB- -LRB-) (ADJP (JJ right)) (-RRB- -RRB-))) (. .)) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (PP (IN As) (PP (IN in) (NP (-LRB- -LRB-) (NN A) (-RRB- -RRB-)))) (, ,) (CC but) (NP-SBJ-1 (NP (DT the) (NN pulse)) (PP (IN to) (NP (CD 0) (NNS mV)))) (VP (VBD was) (VP (VBN preceded) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (DT a) (NML (CD 200) (HYPH -) (NNS ms)) (NN conditioning) (NN depolarization)) (PP (IN to) (NP (QP (SYM +) (CD 10)) (NNS mV))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NN ω) (HYPH -) (NN Conotoxin)) (VP (VBD was) (PP-PRD (IN without) (NP (NP (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ current)) (VP (VBN measured) (NP (-NONE- *)) (PP-TMP (IN during) (NP (NP (DT the) (NN depolarization)) (PP (IN to) (NP (CD 0) (NNS mV))))) (PP (IN under) (NP (DT these) (NNS conditions) (PRN (-LRB- -LRB-) (ADJP (JJ right)) (-RRB- -RRB-)))))))))) (. .))) )
( (CAPTION (FRAG (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP (JJ Top)) (: :) (NP (NP (JJ peak) (NN Ca2+) (NNS currents)) (VP (VBN measured) (NP (-NONE- *)) (PP (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NML (CD 2) (NNS μM)) (NN isradipine)) (ADVP (RB alone)) (PRN (-LRB- -LRB-) (NP (JJ open) (NNS squares)) (-RRB- -RRB-)))))) (CC or) (PP (ADVP (RB together)) (IN with) (NP (NML (CD 1) (NN μM)) (NN ω) (HYPH -) (NN conotoxin) (PRN (-LRB- -LRB-) (NP (JJ red) (NNS circles)) (-RRB- -RRB-))))) (PP-TMP (IN during) (NP (NP (DT a) (NN depolarization)) (PP (IN to) (NP (CD 0) (NNS mV))) (PP-TMP (IN following) (NP (NP (NML (CD 200) (HYPH -) (NNS ms)) (NN conditioning) (NNS pulses)) (PP (IN to) (NP (QP (IN between) (QP (SYM −) (CD 70)) (CC and) (QP (SYM +) (CD 70))) (NNS mV))))))))) (. .))) )
( (CAPTION (FRAG (ADJP (JJR Lower)) (: :) (NP (NP (NN inactivation)) (PP (IN of) (NP (DT the) (ADJP (NP (NN ω) (HYPH -) (NN conotoxin)) (HYPH –) (JJ sensitive)) (NN component)))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (ADJP (RB Half) (HYPH -) (JJ maximal)) (NN inactivation)) (PP (IN of) (NP (DT the) (NML (NN N) (HYPH -) (NN type)) (NN current)))) (VP (VBD was) (PP-PRD (IN at) (NP (QP (QP (SYM −) (CD 31)) (SYM ±) (QP (CD 6))) (NNS mV) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 5)))) (-RRB- -RRB-))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (NP-SBJ-1 (NN Exocytosis)) (VP (VBD was) (VP (VBN elicited) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NML (CD 500) (HYPH -) (NNS ms)) (NNS depolarisations)) (PP (PP (IN from) (NP (QP (SYM −) (CD 70)) (NNS mV))) (PP (IN to) (NP (QP (IN between) (QP (SYM −) (CD 50)) (CC and) (QP (CD 20))) (NNS mV)))))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS E) (-RRB- -RRB-)) (NP (DT The) (NN voltage) (NN dependence)) (PP (IN of) (NP (DT the) (JJ exocytotic) (NN response))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS F) (-RRB- -RRB-)) (NP (NN Exocytosis)) (VP (VBN elicited) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NP (NML (CD 500) (HYPH -) (NNS ms)) (NNS depolarisations)) (PP (IN to) (NP (CD 0) (NNS mV))))) (PP (IN from) (NP (NP (VBG holding) (NNS potentials)) (PP (IN of) (NP (QP (IN between) (QP (SYM −) (CD 70)) (CC and) (QP (SYM −) (CD 30))) (NNS mV)))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS G) (-RRB- -RRB-)) (NP (NN Summary)) (PP (IN of) (NP (NP (NNS effects)) (PP (IN of) (NP (NN holding) (NN potential))) (PP (IN on) (NP (NP (JJ exocytotic) (NNS responses)) (VP (VBN elicited) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NP (NNS depolarisations)) (PP (IN to) (NP (CD 0) (NNS mV)))))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NNS Data)) (VP (VBP have) (VP (VBN been) (VP (VBN normalized) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (NNS responses)) (VP (VBN obtained) (NP (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT a) (NN holding) (NN potential)) (PP (IN of) (NP (QP (SYM −) (CD 70)) (NNS mV)))))))))))) (. .))) )
( (CAPTION (S (S (S-FRM (SYM *) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (SYM **) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (SYM ***) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (PP (VBN compared) (PP (PP (IN with) (NP (NN ω) (HYPH -) (NN conotoxin) (PRN (-LRB- -LRB-) (NP (NN C)) (, ,) (ADJP (JJ top)) (-RRB- -RRB-)))) (CC or) (PP (IN with) (NP (DT the) (JJ initial) (NN response))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 10))) )
( (HEADING (NP (NP (DT A) (NN Model)) (PP (IN for) (NP (NP (DT the) (NN Suppression)) (PP (IN of) (NP (NN Glucagon) (NN Secretion))) (PP (IN by) (NP (DT an) (JJ Intrinsic) (NML (NN α) (HYPH -) (NN Cell)) (NN Pathway))))))) )
( (CAPTION (S (NP-SBJ-1 (NP (JJ Schematic) (NN representation)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN glucose) (, ,) (NN tolbutamide) (, ,) (CC and) (NN diazoxide))) (PP (IN on) (NP (NP (NML (NML (NML (NML (NN α) (HYPH -) (NN cell)) (NN KATP)) (, ,) (NML (NN Na+)) (, ,) (CC and) (NML (NML (NN N) (HYPH -) (NN type)) (NN Ca2+) (PRN (-LRB- -LRB-) (NP (NN VDCC)) (-RRB- -RRB-)))) (NN channel)) (NNS activities)) (CC and) (NP (NN glucagon) (NN secretion))))))) (VP (VBZ is) (VP (VBN shown) (NP-1 (-NONE- *)))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (DT The) (NN insulin) (NN response)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN shown) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NP (NN comparison)) (PP (IN with) (NP (PRP$ our) (JJ experimental) (NNS results))))) (PRN (-LRB- -LRB-) (NP (JJ dashed) (NNS lines)) (, ,) (NP (JJR lower) (NNS panels)) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (S (NP-SBJ (DT The) (JJ grey) (NN gradient)) (VP (VBZ represents) (NP (NP (NP (DT a) (`` “) (NN window)) ('' ”) (PP (IN of) (NP (NML (NML (NML (NN α) (HYPH -) (NN cell)) (NN KATP)) (NN channel)) (NN activity)))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ supports) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NML (NN Ca2+) (CC and) (NN Na+)) (NNS channels))))))))) (. .))) )
( (CAPTION (S (PP (IN Above) (NP (DT this) (NN window))) (, ,) (S (S (S (NP-SBJ-2 (DT the) (NN cell)) (VP (VBZ is) (VP (VBN hyperpolarized) (NP-2 (-NONE- *))))) (CC and) (S (NP-SBJ-1 (NML (NML (NN Ca2+) (CC and) (NN Na+)) (NN channel)) (NN activation)) (VP (VBZ is) (VP (VBN prevented) (NP-1 (-NONE- *)))))) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ (NP (NML (NN KATP) (NN channel)) (NN activity)) (PP (IN below) (NP (DT this) (NN window)))) (VP (VP (VBZ depolarizes) (NP (DT the) (NN cell))) (CC and) (VP (VBZ causes) (NP (NP (ADJP (NN voltage) (HYPH -) (JJ dependent)) (NN inactivation)) (PP (IN of) (NP (NML (NN Ca2+) (CC and) (NN Na+)) (NNS channels))))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ (NML (JJ High) (HYPH -) (NN glucose)) (NN concentration)) (VP (VBZ reduces) (NP (NML (NML (NML (NN α) (HYPH -) (NN cell)) (NN KATP)) (NN channel)) (NN activity)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG reducing) (NP (NN glucagon) (NN secretion))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP-SBJ (NP (VBN Graded) (NN application)) (PP (IN of) (NP (NN tolbutamide))) (-LRB- -LRB-) (PP (IN in) (NP (CD zero) (NN glucose))) (-RRB- -RRB-)) (ADVP (RB transiently)) (VP (VBZ increases) (NP (NN glucagon) (NN secretion)) (SBAR-ADV (IN as) (S (NP-SBJ-1 (NML (NN KATP) (NN channel)) (NN activity)) (VP (VBZ is) (VP (VBN reduced) (NP-1 (-NONE- *)) (PP (PP (IN through) (NP-2 (-NONE- *RNR*))) (, ,) (CC and) (PP (ADVP-TMP (RB eventually)) (IN below) (NP-2 (-NONE- *RNR*))) (, ,) (NP-2 (NP (DT the) (NN window)) (VP (VBG supporting) (NP (NN glucagon) (NN release)))))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP-SBJ (NP (DT The) (VBN graded) (NN application)) (PP (IN of) (NP (NN diazoxide))) (PP (IN in) (NP (NML (JJ high) (HYPH -) (NN glucose)) (NNS conditions)))) (VP (VBZ increases) (NP (NML (NN α) (HYPH -) (NN cell)) (NML (NN KATP) (NN channel)) (NN activity)) (PP (PP (IN into) (NP-1 (-NONE- *RNR*))) (, ,) (CC and) (PP (ADVP-TMP (RB then)) (IN above) (NP-1 (-NONE- *RNR*))) (NP-1 (NP (DT the) (NN window)) (VP (VBG supporting) (NP (NN glucagon) (NN secretion)))))) (. .))) )
( (CAPTION (S (NP-SBJ (DT The) (NN result)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ transient) (`` “) (NN re-activation)) ('' ”) (PP (IN of) (NP (NN glucagon) (NN secretion))) (PP (IN at) (NP (NML (JJ low) (HYPH -) (NN diazoxide)) (NNS concentrations))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (PP (IN In) (NP (NML (JJ low) (HYPH -) (NN glucose)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (SYM –) (CD 2)) (NNS mM)) (-RRB- -RRB-)) (NNS conditions))) (, ,) (NP-SBJ (NP (VBN graded) (NN application)) (PP (IN of) (NP (NN diazoxide)))) (VP (VBZ increases) (NP (NML (NN KATP) (NN channel)) (NN activity)) (PP (IN above) (NP (NP (DT the) (NN window)) (VP (VBG supporting) (NP (NN glucagon) (NN secretion))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG causing) (NP (NP (DT a) (JJ monotonic) (NN inhibition)) (PP (IN of) (NP (NN glucagon) (NN release))))))) (. .))) )
( (HEADING (NP (NNS Footnotes))) )
( (HEADING (NP (JJ Competing) (NNS interests) (. .))) )
( (S (NP-SBJ (DT The) (NNS authors)) (VP (VBP have) (VP (VBN declared) (SBAR (IN that) (S (NP-SBJ (DT no) (VBG competing) (NNS interests)) (VP (VBP exist)))))) (. .)) )
( (HEADING (NP (NN Author) (NNS contributions) (. .))) )
( (S (NP-SBJ (NNP PEM) (, ,) (NNP LE) (, ,) (CC and) (NNP PR)) (VP (VBD conceived) (CC and) (VBD designed) (NP (DT the) (NNS experiments))) (. .)) )
( (S (NP-SBJ (NNP PEM) (, ,) (NNP YZDM) (, ,) (NNP RR) (, ,) (NNP AS) (, ,) (NNP XM) (, ,) (CC and) (NNP LE)) (VP (VBD performed) (NP (DT the) (NNS experiments))) (. .)) )
( (S (NP-SBJ (NNP PEM) (, ,) (NNP YZDM) (, ,) (NNP RR) (, ,) (NNP AS) (, ,) (NNP LE) (, ,) (CC and) (NNP PR)) (VP (VBD analyzed) (NP (DT the) (NNS data))) (. .)) )
( (S (NP-SBJ (NNP PRVJ) (CC and) (NNP RC)) (VP (VBD contributed) (NP (NP (NNS reagents)) (HYPH /) (NP (NNS materials)) (HYPH /) (NP (NN analysis) (NNS tools)))) (. .)) )
( (S (NP-SBJ (NNP PEM) (CC and) (NNP PR)) (VP (VBD wrote) (NP (DT the) (NN paper))) (. .)) )
( (HEADING (NP (NN Funding) (. .))) )
( (S (NP-SBJ-1 (NP (NN Work)) (PP-LOC (IN in) (NP (DT the) (NNP UK)))) (VP (VBD was) (VP (VBN supported) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NNS grants)) (PP (IN to) (NP (NN PR))) (PP (IN from) (NP (NP (DT the) (NNP Wellcome) (NNP Trust)) (CC and) (NP (DT the) (NNP European) (NNP Union)))) (PRN (-LRB- -LRB-) (NP (NP (NNP Eurodia) (NN LSHM) (HYPH -) (NN CT) (HYPH -) (CD 2006) (HYPH –) (CD 518153)) (CC and) (NP (NNP BioSim) (NN LSHB) (HYPH -) (NN CT) (HYPH -) (CD 2004) (HYPH –) (CD 005137))) (-RRB- -RRB-)))))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Work)) (VP (VBN conducted) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NNP Sweden))))) (VP (VBD was) (VP (VBN supported) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (DT the) (NNP Swedish) (NNP Strategic) (NNP Foundation)) (, ,) (NP (DT the) (NNP Göran) (NNP Gustafsson) (NNP Stiftelse)) (, ,) (NP (DT the) (NNP Swedish) (NNP Research) (NNP Council)) (, ,) (NP (DT the) (NNP Swedish) (NNP Diabetes) (NNP Association)) (, ,) (CC and) (NP (DT the) (NNP Novo) (NNP Nordisk) (NNP Foundation)))) (PRN (-LRB- -LRB-) (NP (NNP LE)) (-RRB- -RRB-)))) (. .)) )
